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ABSTRACT
Respiratory infections with the virulent type A strains of Francisella tularensis (Ft) cause
pneumonic tularemia, an illness which results in high case fatalities in the absence of
timely antibiotic treatment. Although immunization is an effective countermeasure,
vaccines against pulmonary tularemia are currently unavailable. A better understanding
of protective immune components is therefore needed to develop licensable vaccines
against pulmonary tularemia. While the indispensability of cell-mediated immunity in
protection against this gram-negative intracellular bacterium is well-documented, the
protective role of antibodies (Abs) is unclear. Hence we examined the role of humoral
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immunity by developing a passive immunization model of respiratory tularemia in
Fischer 344 (F344) rats. Naïve F344 rats treated prophylactically with immune rat serum
(IRS) or purified immune IgG obtained from rats vaccinated subcutaneously with the
attenuated live vaccine strain (LVS) were protected against a lethal intratracheal infection
with Ft type A strain SCHU S4. The resistance conferred by IRS was dependent on both
anti-serum volume and SCHU S4 challenge dose, and was abrogated when IRS treatment
was delayed beyond 48 h after the infection. Ab-mediated protection correlated with
decreased dissemination to liver and spleen where the histopathology was less severe and
depended on CD8 T cells. In vitro and in vivo bacterial burden analyses implicated other
protective mechanisms of IRS in addition to enhancing phagocytosis and delaying
bacterial growth. Further experimental analyses showed decreased levels of
inflammatory cytokines and tissue damage markers in the sera and tissues of IRS-treated
rats, which also showed markedly decreased apoptosis in their lungs. At the peak of
infection, unlike the lung-associated lymph nodes (LALN) of normal serum treated rats,
LALN of IRS-treated rats had lower SCHU S4 burden and higher number of viable
dendritic cells, T cells, B cells and IFNγ –secreting cells. These results therefore
demonstrate the ability of Abs to limit inflammation and cell death during pulmonary
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SCHU S4 infection to generate protective immunity and have important implications for
understanding SCHU S4 virulence and development of Ab-based vaccines and
therapeutics.
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CHAPTER 1: INTRODUCTION

1

Mammalian host defenses
Mammals are persistently exposed to microbes and foreign particles due to their
cohabitation. The consequences of a viable entry could be dire- disrupting the
homeostasis to result in morbidity and death. In order to detect, combat, and overcome
the invasion of ‘non-self’ antigens and survive the deleterious consequences, the
mammalian host has evolved immune defenses broadly categorized as innate and
adaptive or acquired immune systems(1, 2). Constituents of the innate immunity are at
the vanguard of the immune response continuum and are the first to sense the entry of
foreign entity in to the host after they break through the physical barriers in place (skin,
mucus). The resulting inflammatory response is rapid and acute and is initiated by the
engagement of germline-encoded specialized transmembrane proteins called pattern
recognition receptors (PRR) expressed constitutively on phagocytes, fibroblasts,
endothelial and epithelial cells(3-5). PRRs by virtue of broad specificity recognize
unique molecular signatures called pathogen-associated molecular patterns (PAMPs),
which are highly conserved structures critical for pathogen survival. In addition, PRRs
can sense endogenous danger signals termed damage-associated molecular patterns
(DAMPs), released from damaged cells (2, 6, 7). Successful detection of danger at the
host’s doorstep triggers signaling cascades, which result in the development of
inflammatory responses characterized by the prototypical transcriptional upregulation of
proinflammatory cytokines like tumor necrosis factor (TNF), interleukin-6 (IL-6), and
interleukin-1 (IL-1) (8). These have pleiotropic effects and orchestrate the activation of
several downstream pathways that contribute significantly towards overwhelming the
pathogen. The early inflammatory responses are vital for controlling pathogen
2

multiplication and/or dissemination but are inadequate to eliminate the pathogen and
clear the infection. Adaptive immune responses may therefore be necessary for pathogen
clearance.
Adaptive immunity spearheaded by B and T lymphocytes gains maximal effect 710 days after the initial innate immune activation and is activated by B- and T-cell
receptors’ binding to their cognate antigenic epitopes derived from pathogens in the
regional secondary lymphoid organs. The receptors recognize antigenic epitopes with
remarkable specificity and are expressed after their germline-encoded gene segments
undergo extensive rearrangements during lymphocyte development. Upon stimulation,
antigen-specific T and B cells undergo clonal expansion and resolve the infection
completely. B lymphocytes exert their control primarily through antibody (Ab)
production. Both CD4 and CD8 T cells secrete cytokines that activate several
downstream pathways that help control the infection. In addition, CD8 T cells also have
the ability to lyse infected cells and limit the infection. Repeat infections with pathogens
are hence comparatively limited due to the heightened and brisk response of memory T
and B cells. The regulated and combined actions of both innate and adaptive immune
arms control and eliminate infections.
Stimulation of specific PRRs has been shown to significantly affect the
phenotype, magnitude, and longevity of antigen-specific B cell responses (9, 10). Thus
innate immune cells dictate the specific nature of adaptive immune responses and vice
versa (11, 12). Cytokine release by CD4+ T cells activates macrophages and dendritic
cells (DCs) to enhance antigen processing and peptide presentation in the grooves of
major histocompatibility (MHC) molecules of antigen presenting cells (APCs). In
3

addition, B cell activation and differentiation is affected by the T cell cytokine profiles in
the microenvironment. B cells also express the necessary costimulatory molecules for T
cell activation and also secrete specific Abs which may activate the innate classical
pathway of complement. Once activated, the adaptive immune responses amplify and
enhance innate immune system functions by activating the various components of the
innate immune system (13, 14). Host actions resulting in the development of immunity
therefore exist in a web of interdependent pathways layered in complexity, and require
well-orchestrated and synergistic actions of different arms of the immune response to
clear the infection. The aforementioned basic tenets of the host immune response form
the core of design and efficacy of vaccines and adjuvants and are integral to the current
thesis.

Vaccines
Vaccines have come to signify major public health interventions of the 20th
century and continue to be instrumental in saving millions of lives and dollars by
preventing several diseases, which otherwise pose a serious threat of unimaginable
proportions to global health. Small pox was successfully wiped out and the number of
polio cases has been brought down to near-eradication levels due to vaccines (15, 16).
The benefits of vaccine administration is further illustrated by the steep drop in the
number of cases of several vaccine-preventable diseases like diphtheria, measles, and
diarrheal diseases with increase in the vaccinated population percentage across all the
continents (15). In view of vaccines’ success and the burden of several emerging and reemerging infectious diseases to the exchequer and general public health, efforts to
4

develop vaccines against these pathogens are a priority. Development of most of the
currently licensed vaccines however remains the greatest irony, since they are all
empirical derivatives, developed with the minimal understanding of vaccine modus
operandi in the context of human immune system. However, current licensure of
vaccines and other biological products for biothreats and emerging infections, which are
not ethical or feasible for human testing, requires efficacy testing in animal models under
‘the Animal Rule’ drafted by the FDA (17). Therefore, understanding the basis for
protection elicited by novel vaccine candidates in animal models is vital for developing
licensed vaccines that are safe and provide long-lasting efficacy to humans against
dangerous pathogens for which vaccines are not yet available. This protection relies
mainly on the sustained and adequate responses of the acquired immune system.
Abs can thwart infection by binding to the epitopes on pathogens’ surface and
blocking their interaction with the host cell surface receptors. Extracellular virulence
factors like toxins are also neutralized by Abs. Due to their purported presence and
activity only in the extracellular milieu, Abs were hence deemed to be critical for
protection only against extracellular microbes and a few intracellular pathogens which
predominantly cause virulence due to secretion of toxins which circulate outside the cells.
Cellular adaptive immunity, mediated by T cells, was thought to be indispensible against
intracellular bacteria and viruses. However, evidence arguing against the rigidity of this
immunological division of labor has been increasing (18, 19).

5

Immune system duality and Abs’ role against intracellular pathogens
Pathogens can escape the potency of Ab functions through their inherent obligate
intracellular lifestyle, immune exclusion, or by secreting virulence factors. Engulfed
pathogens enter either MHC I or II antigen processing pathways and thereby come under
the influence of CD8 and CD4 T cells, respectively. Proteins of pathogens sampled by
APCs in to the phagosomes are processed in to peptides and presented to CD4 T cells in
complex with MHC II molecules. CD8 T cells recognize their cognate peptide-MHC I
complexes which are formed from processed antigens of cytosolic bacteria and viruses
known to synthesize proteins and replicate in the cytosol. The pathogen load is
significantly decreased after the T cells expand clonally and differentiate to amplify their
effector functions (20). Thus, intracellular pathogens that are able to evade Ab functions
are controlled by T cells. The failure to demonstrate the critical role of Abs and the
growth of experimental evidence supporting the indispensability of T cells in protection
against intracellular pathogens gave rise to the immunological duality paradigm(19).
The failure of Abs to protect the host against an intracellular pathogen does
necessarily not rule out the benefit they provide. For, Ab specificity, dose, isotype,
idiotype, inoculum strain and dose, and host characteristics have all been shown to alter
the outcome of infection when Abs were tested (21-24). The interdependence of both T
and B cells in facilitating a potent immune response has further blurred the lines between
humoral and cell-mediated arms of the immune system and the scope of benefit they
provide against intra- and extracellular pathogens respectively. In addition, pathogens
hitherto thought to be intracellular were shown to be present outside the cells, thereby
making them susceptible to Ab actions. For example, specific Abs against Erhlichia
6

chaffensis, an obligate intracellular bacterium, protected both normal and SCID mice.
This pathogen was later shown to be present extracellularly (25, 26). However, Ab
activity is not restricted to the extracellular environment alone. Intracellular growth of
Listeria monocytogenes in infected macrophages is significantly controlled by mAbs
against listeriolysin O (LLO), a pore-forming toxin necessary for the bacterial escape
from the phagosome in to the cytosol (27). The mAbs neutralized LLO intracellularly
and restricted the bacterial number independent of FcγRs, IFNγ-signaling, or reactive
oxygen species (ROS) and reactive nitrogen species (RNS) production. Intracellular
neutralization of viruses by IgA during transcytosis and targeting viruses for proteasomal
degradation in the cytosol by IgG has also been shown (28, 29). Hence Abs alone, or in
conjunction with CMI, may benefit the host in protection against intracellular pathogens.
The protective role of Abs against virulent type A strains of F. tularensis, a facultative
intracellular pathogen, during a respiratory infection is unclear and is the principal
objective of this thesis.

Francisella tularensis: strains, life cycle and virulence
Discovered 100 years ago in the rodents of Tulare County, California, F.
tularensis is a 0.2 µm x 0.2-0.7 µm-sized coccobacillus, which infects a wide range of
hosts across different phyla (30-32). Humans contract tularemia through direct contact
with infected animals and vector bites in addition to ingesting and inhaling contaminated
material and infectious aerosols, respectively (33-36). After an incubation period of 3-5
days, patients develop flu-like symptoms with swollen lymph nodes and the illness may
protract or relapse in the absence of prolonged treatment with aminoglycosides (37, 38).
7

Infection by the oral, ocular, respiratory routes causes oropharyngeal or gastrointestinal,
oculoglandular, and pneumonic or respiratory tularemia respectively. Disease severity is
dependent on the route of infection, inoculum dose and strain (31). Irrespective of the
route of entry, Francisella disseminates to several tissues such as lungs, lymph nodes,
spleen, liver, kidneys, and intestines, where it multiplies.
F. tularensis is divided in to three subspecies based on the geographical
distribution and virulence in humans (39). F. tularensis subsp. mediasiatica found in
Central Asia is nonpathogenic while F. tularensis subsp. holarctica (type B or biovar B)
causes widespread recoverable mild disease in the European populations and is highly
virulent in murine infections. Of the three subspecies, F. tularensis subsp. tularensis
(type A or biovar A) endemic to North America is the most virulent in humans.
Epidemiological studies have recently classified these subspecies further in to three
clades Ala, A1b, and A2 based on differences in virulence in humans (40, 41). Airway
infection with as few as 10 type A strain bacilli may result in a productive infection and
could be fatal in one-third of patients in the absence of treatment (42). Investigators
routinely employ three different strains in their studies-live vaccine strain (LVS), SCHU
S4, and U112. SCHU S4 is a type A strain of subsp. tularensis while LVS is an
attenuated form of subsp. holarctica developed through serial passages and the current
vaccine gold standard. U112 is a strain of F. novicida, a closely related species of
Francisella, which shares a high degree of homology to subsp. holarctica and tularensis.
It is avirulent in humans but causes lethal disease in rodents and is also used as a model
for F. tularensis due to the ease of genetic manipulation and less restrictive
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biocontainment requirements. The virulence, target cells, and immunogenicity of the
strains differ significantly from each other (Table I).
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Table I. Comparison of virulence characteristics of different Francisella strains ((43-54).
Strain

Humans

Mice
(C57BL/6J)

Rats (F344)

Target cellsa

Phenotypic
activation of
APC

Cell Death

Type
A1a/b Ft

Highly virulent, can
be lethal

LD50<10 by all
routesb

LD99<100 IT,
>105 SC

AMs/DCs>

Apoptosis

Neutrophils

Inhibited in
mice during
respiratory
infection

Type A2
Ft

Causes morbidity
but rarely lethal

LD50<10 by all
routes

ND

ND

ND

ND

Type B
Ft

Causes morbidity
but rarely lethal

LD50<10 by all
routes

LD50 105 IT,
<10 IP

ND

ND

ND

LVS

Vaccine strain,
Attenuated type B,
Productive infection
by airways and skin

LD50 103IN, 106
ID, <10 IP or IV,
Sublethal doses
used for
vaccination

LD50 105 IT,
IP >108,
Sublethal
doses used for
vaccination

AMs/DCs>

Pyroptosis,
apoptosis

Neutrophils

Seen in both
human and
mouse
macrophages
in vitro

Infections rare,
Cases in
immunocompromise
d individuals

LD50 <10 IP, IV,
or IN, 103ID,
Sublethal doses
used for
vaccinating mice

LD50 5 x 106

Neutrophils>

ND

Pyroptosis,
apoptosis

F.
novicida

AMs/DCs

a

Cells targeted during i.n. challenge
Approximate lethal dose values expressed as CFU
ND, Not determined; APC, antigen presenting cells; AMs, alveolar macrophages; DCs, dendritic cells; IT, intratracheal; IP, intra-peritoneal; ID, intradermal; IV, intravenous; SC, sub-cutanaeous.
b
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F. tularensis infects a wide range of mammalian cells which include mononuclear
phagocytes, neutrophils, hepatocytes, erythrocytes, B cells, and fibroblasts, epithelial and
endothelial cells (52, 55-61). Neutrophil and DC uptake of Francisella is opsonindependent while macrophages also phagocytose the pathogen through opsoninindependent mechanisms by ‘looping phagocytosis’ (Figure 1) (62-64). Opsonization
with freshly isolated naïve serum facilitates increased bacterial engulfment
predominantly by complement receptor CR3 (CD11b/CD18) (62, 65). Serum
opsonization also results in Francisella uptake by the scavenger receptor class A (SRA),
FcγRs, nucleolin, and lung surfactant protein A (SPA) (62, 66, 67). Non-opsonized
Francisella is phagocytosed through the mannose receptor (68). The ingested bacteria
reside for a short time period in the phagosome and interact with the early and late
endocytic compartments (65, 69-71). The phagosome does not acquire Cathepsin D and
other lysosomal tracers and hence, fails to mature in to a phagolysosome (65, 72, 73).
Subsequent acidification of the phagosome has been shown to activate the virulence
genes necessary for the phagosome membrane disruption and escape in to the cytosol (70,
74). Phagosome disruption and cytosolic entry from the vesicular components is
strategically critical for Francisella survival since infection of macrophages with
phagosome escape-deficient mutants results in decreased bacterial numbers (71, 72, 75).
Once in the cytosol, Francisella proliferates during the next 24h and is released from the
cells through caspase-dependent lysis (52, 76-78). Thus phagosome escape followed by
cytosolic replication and induction of host-cell apoptosis may explain part of the
pathogenesis caused by all Francisella strains.

11

Figure 1. Intracellular lifestyle of Francisella sp. in the macrophages. (1) Francisella enters macrophages
by ‘looping phagocytosis’ using different receptors. (2) The engulfed bacteria reside transiently in
Francisella-containing phagosome (FCP). (3) The FCP interacts with early endosome (EE) and late
endosomes (LE) but the bacteria inhibit fusion with the lysosomes (Lys). Phagosome acidification triggers
protein synthesis necessary for phagosomal disruption and escape in to the cytosol. (4) Post-phagosome
disruption, the bacteria escape in to the host cell cytosol. (5)Replication in the cytosol. (6) Host cell death
by apoptosis or pyroptosis releases the bacteria which go on to infect other cells (79-81).
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The genomic sequences of LVS, SCHU S4, and U112 are >97% identical (82).
Nonetheless, only type A and B strains are pathogenic to humans and only infections
with subsp. tularensis result in severe morbidity and fatalities. The difference in
outcomes may be due to varied virulence determinants between the three strains. All
three strains encode the Francisella pathogenicity island (FPI), a ~30kb locus encoding
17 genes required for phagosome escape and intracellular multiplication (83-86). The
pathogenic strains encode two copies of FPI while F. novicida has only one copy (87).
However, it has not been determined whether the FPI copy number has any correlation
with the virulence. During an intranasal (i.n) infection, F. novicida targets the lung
neutrophils and AMs before multiplying in the neutrophils while the pathogenic strains
preferentially infect the AMs and later proliferate in AMs, DCs, and PMNs (88). The
LPS of F. novicida differs from that of the pathogenic strains in having two novel sugars
in the repeating carbohydrate tetramer of O antigen (89, 90).
The virulence of type A strains stems from their ability to survive and proliferate
to significant levels undetected during the first 48h in the host cells (91-94). Facilitating
its virulence is the tetra-acylated nature of type A strain’s LPS, which is distinct from the
hexa-acylated LPS of E. coli and Salmonella spps (95, 96) and does not induce an innate
immune response. The lack of two acyl groups makes it a poor stimulatory agent of
TLR4 unlike E. coli LPS, a potent TLR4 agonist. The preferential tropism of SCHU S4
to AMs and DCs during pulmonary infection may also render it undetectable by the host
cells due to their lack of CD14 leading to increased virulence (97). This co-receptor
enhances binding of microbial ligands to TLR2 and was shown to be associated with
increased production of TNF-α and IL-6 and bacterial control when administered
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exogenously. Human myeloid dendritic cells (mDCs) directly infected with SCHU S4 as
well as bystander cells are impaired in their ability to respond to the pathogen as well as
secondary stimuli (98). In addition, DCs of mice infected with SCHU S4 aerosols are not
activated and show decreased expression of co-stimulatory molecules, MHC II, and
inflammatory molecules (55). On the contrary, the infected animals produced the antiinflammatory tumor growth factor-β (TGFβ) and did not respond to LPS administered
i.n. Early studies in aerogenically infected tularemic patients also reported similar
unresponsiveness to S. typhosa and E. coli endotoxins (99). Together these mechanisms
act to increase the ‘stealth’ nature type A Ft strains.
Other inherent mechanisms contribute towards SCHU S4 virulence. The virulent
strains utilize the CR3 under opsonizing conditions and mannose receptors (MRs) in the
absence of opsonins to invade the macrophages (68). This provides a strategic advantage
to the pathogen as the entry through these receptors is devoid of respiratory burst. On the
other hand, FcγR-mediated uptake triggers the bacteria-damaging ROS production, but
the virulent strains have also developed a mechanism to combat this host defense. SCHU
S4, but not LVS, binds to the host serine protease plasmin to degrade the binding Ab and
thereby prevents opsonization, phagocytosis, and the associated TNF-α and IL-6
production (100). Biovar A strains can also weather the bactericidal effects of ROS
through efficient regulation of iron metabolism. Their relatively low iron content and
stringent regulation of iron uptake and storage makes them more resistant to H2O2 by
preventing the formation of bactericidal hydroxyl radicals and anions (101). In addition
to catalase, the virulent strains also have other unidentified mechanisms to neutralize the
host ROS (102). An array of factors, host-derived and inherent to the pathogen, hence
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contributes towards the virulence of type A strains. Therefore, host immune components
that protect even in the presence of pathogen’s virulent factors are crucial for effective
treatments.

Innate immunity against respiratory F. tularensis infections
The improved understanding of Francisella lifestyle and virulence is the result of
numerous in vitro studies with mononuclear phagocytes since these cells are converted to
safe niches for their growth through several previously described subversive mechanisms.
Both pathogenic strains multiply exponentially in macrophages and dendritic cells
isolated from peripheral blood, lungs, peritoneal cavity, bone marrow of several species
(45, 97, 98, 101-105). In vitro model systems that examine intra-phagocyte Francisella
growth have been developed and are routinely used to identify protective immune
correlates and effector molecules induced by vaccines and therapeutics (69, 106, 107).
The intracellular bacterial proliferation has been shown to ultimately result in
macrophage apoptosis during a pulmonary SCHU S4 infection (52). This has led
researchers to postulate that the death of these innate immune cells prevents adequate
development of protective immunity (51, 52). On the other hand, elimination of these
cells could be eliminating Ft growth foci, since Francisella preferentially infects and
multiplies in the phagocytes. This immune cell destruction may therefore benefit the
host. However, the absence of macrophage-deficient models makes their protective role
currently unclear. Similarly, although altered DC function during murine pulmonary
infection has been suggested, their role in enabling host survival has not been directly
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examined (55, 94). Type A strains also target other innate immune cells and their
importance in protection is beginning to be understood.
Neutrophil response to infection is rapid and is a result of neutrophil extracellular
traps (NETs), bactericidal granules, and the highly reactive superoxide radicals. During a
murine pulmonary infection with SCHU S4, a dose effect in neutrophil recruitment to the
lungs is observed (88, 108). Neutrophil influx and bacterial uptake by itself did not
provide any benefit to the host, since neither neutrophil depletion nor early recruitment
decreased the bacterial burden or improved the survival, respectively (108, 109). These
innate immune cells are in turn converted to safe havens by the virulent strains which
inhibit NADPH oxidase assembly in the phagosome and escape in to the cytosol (110).
However, knockout studies revealed a limited role for this enzyme suggesting other
crucial mechanisms at play (108).
Mouse pneumonic infections with LVS suggest the important function of IFNγ
production by NK cells during the first week of infection (111-113). Their effect is
pronounced in liver where they were shown to be indispensible for pyrogranuloma
formation and thereby restricting hepatic bacterial spread (111). But the benefit of
elevated IFNγ secretion is not translated in to an improved outcome against SCHU S4,
since NK cell-depletion did not alter the resistance significantly (104). SCHU S4
infection of murine hepatic NK cells also increased IFNγ production when supplemented
with recombinant IL-12 and IL-18 in vitro (114). However, their protective in vivo
function(s) during respiratory infection with SCHU S4 and cell lysing function have not
been studied yet.
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Alveolar epithelial type I (ATI) and type II (ATII) cells line the pulmonary
mucosal cavity, making them highly susceptible for interaction with Francisella during a
pulmonary infection. In support of this hypothesis, SCHU S4 stimulated human primary
ATII cells secreted chemokines through NF-κB activation to induce transmigration of
neutrophils and DCs across primary human pulmonary microvasculature endothelial cells
(58). Although the protective role of mast cells through IL-4 secretion has been reported
during pulmonary LVS infection, their role with regard to SCHU S4 is yet to be studied
(107, 115, 116).

T cell adaptive immunity against respiratory F. tularensis infections
T cells are central to vaccine-induced protection by inducing anamnestic
responses upon infection with several intracellular pathogens. A vaccinated state that
protects against subsequent infections is induced in humans naturally infected with
Francisella despite developing illness (117). Safe vaccines that generate sustained
protective immune responses are necessary to limit casualties from intentional aerosol
release of type A strains. Several vaccination protocols in murine models consistently
implicate the critical role of T cells against pulmonary tularemia caused by type A
biovars (118-121). Of these, the respiratory route of vaccination with LVS and SCHU
S4-mutants provided reliable protection against lethal pulmonary infection, which was
mediated by CD4, CD8 and NK T cells (118, 121). Data from the in vitro model systems
developed by Elkins & co-workers conclude that the IFNγ production by primed CD4+ T
cells is paramount for activating macrophages and controlling intracellular Francisella
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growth (43, 122, 123). On the other hand, CD8 T cells produce the same aforementioned
effect through TNFα (124). In the absence of both T cell subsets, primary i.n. LVS
infection results in a long-term chronic infection due to their inability to clear the bacteria
(125). Compared to parenteral routes, vaccinating the airways with LVS induced the
higher multiplication and accumulation of DN T cells in the lungs and correlated with
improved outcome (125). These MHC-I restricted DN T cells aid in vivo by producing
IL-17 (122, 125). Several groups have reported significant increase in IL-17 during
airway inoculation of mice (91, 125-128). This pro-inflammatory cytokine, produced
significantly higher by DN T cells than the other two subsets, has been shown to exert its
influence by facilitating rapid and increased development of Th1 immunity and
decreasing intracellular bacterial growth in macrophage through synergistic action with
IFNγ (125, 127). IL-17 mediated control in bacterial growth in the lungs was also
observed during a secondary pulmonary challenge with SCHU S4 (91).
The relative robustness of pulmonary vaccination compared to other routes of
vaccination with LVS seen in mice has also been demonstrated in humans (129). But
humans are currently vaccinated in the US under Special Immunization Protocol by
intradermal scarification with LVS. These vaccinees develop T cell-mediated immune
responses (130-132). Although the direct roles of the T cell subsets during severe
pulmonary tularemia have not been tested in humans, and perhaps never will be, in vitro
assays with PBMCs from naturally infected patients and LVS vaccinees produce
significantly high levels of IFNγ, TNFα, IL-17, and IL-2 (133-139). Results from in vitro
intracellular SCHU S4 growth assay from our lab further attest to the protective role of T
cells and IFNγ in LVS-vaccinated humans (Hahn, 2011, manuscript in preparation).
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Depletion of CD4 and CD8 T cells from the PBMCs of LVS vaccinees resulted in the
loss of intracellular SCHU S4 growth restriction. LVS-specific T cell responses are rapid
and effector CD4 and CD8 memory T cell populations were found in the vaccinated
cohort even after scores of years (132, 139-141).

Pulmonary tularemia by type A strains and humoral immunity
Adaptive B cell responses do not correlate with T cell immunity development in
vaccinated humans. These responses, measured through the estimation of LVS-specific
serum IgM, IgG, and IgA titers using microagglutination assay and ELISA are detected
~2 weeks after vaccination (130, 132). The titers were shown to peak within 2 months
and sustain for more than a decade before waning (130, 132, 133, 142). But their
significant presence does not parallel the protective outcome typically associated with T
cell responses. The killed Foshay vaccine used in the pre-antibiotic era which stimulated
a strong Francisella-specific Ab response in the vaccines had relatively higher incidence
of tularemia in vaccinated lab workers than those vaccinated with LVS (143). Other
studies also found dissociation between serum Ab titers and protective capabilities when
killed or inactive vaccines were used (42, 144-147). The protective relevance of Abs
against virulent strains was thus questioned by these studies.
Ab protection studies in mice have yielded similar results with SCHU S4
pulmonary infections. The common finding of these studies was that despite their
presence Abs are protective only against pulmonary infection with the less virulent LVS
or type B but not biovar A strains (109, 148-152). As a result, Abs’ protective role
against virulent respiratory tularemia was considered clinically unimportant until two
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recent studies brought it back to the fore. The oral vaccination study with F. novicida
and the investigation involving passive transfer of immune serum from mice cured of
SCHU S4-induced pulmonary tularemia through laevofloxacin treatment suggested Abmediated protection (44, 153). However, these studies did not explore Ab protective
mechanisms against SCHU S4. Hence Abs’ role against virulent strains is still unclear.

Fischer 344 rat model of pulmonary tularemia
In mice, the limited or no protection mediated by Abs against respiratory
infections with type A strains does not rule out their benefit completely. This is due to
certain inadequacies of the mouse models. All the inbred strains of mice to date display
an extreme inherent susceptibility to even less virulent strains of Francisella-a trait not
seen in immunocompetent humans. While the mouse model is an essential tool to dissect
immunopathological mechanisms of tularemia, it may not be extrapolated to humans.
This is more so with regard to virulent respiratory tularemia. The F344 rat model of
pulmonary tularemia developed in our lab adequately complements the mouse models
(48). Like humans, the F344 rats are highly resistant to LVS vaccination by several
routes and show poor survival against i.t. challenged SCHU S4 unless vaccinated with
LVS, which was shown to increase resistance significantly. The factors contributing
towards protection are not yet determined. The extracellular phase of SCHU S4 reported
recently brings up the possibility of Abs being able to access the pathogen and thereby
influence the infection outcome (59, 154).
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CHAPTER 2: HYPOTHESIS AND AIMS
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Hypothesis and aims
Type A strains of F. tularensis can be easily aerosolized, and due to high infectivity and
extreme virulence by the respiratory route, pose a serious threat to public health in the
event of intentional bioterrorist release (155). Although antibiotics are currently used to
treat infected individuals, their usage is deterred by reports of engineered antibioticresistant strains, development of bacterial resistance, occasional relapse, and financial
constraints (37). Vaccines, on the other hand, have limited drawbacks and can offer
long-term protection. LVS is currently used to vaccinate at-risk individuals as an
investigational drug but is unlikely to be licensed by the FDA due to safety concerns.
Characterization of protective immune components is therefore needed to develop new
licensable vaccines against pulmonary tularemia. The protective mechanism of Abs from
murine models is still unclear. The overall objective my research project was to
determine the role of Abs in protection against pulmonary tularemia caused by type A
strains using the F344 rat model. I hypothesized that Francisella-specific Abs protect
F344 rats against a lethal respiratory infection with F. tularensis type A strain.

AIM 1: Determine if LVS-specific Abs can protect naïve F344 rats against a lethal
i.t. infection with SCHU S4. A protocol for LVS-immunization, immune serum
transfer, and SCHU S4 challenge was developed to explore the protection conferred by
immune Abs induced by LVS vaccination in F344 rats.

AIM 2: Evaluate the role of different T lymphocyte subsets in influencing the
survival in passively immunized rats. Passive immunization experiments with LVS
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suggest the critical role of T cells in the protection mediated by Abs (150, 151). This is
perhaps due to the interdependence of T and B cells for optimal effector functions.
Therefore, we examined the role of T cells in the context of our passive immunization
model.

AIM 3: Examine the potential mechanism(s) of LVS-specific Abs’-mediated
protection against a lethal i.t. SCHU S4 challenge. The dynamics of interactions
between LVS-specific Abs and SCHU S4 in the context of F344 rat as the host and the
resulting outcomes were explored. Ab-mediated SCHU S4 uptake and the resulting
consequences were studied both in vitro and in vivo. We also tested if prophylactic Ab
administration was immunomodulatory in ultimately limiting apoptosis and inflammation
to enable adaptive immunity development.
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CHAPTER 3: MATERIALS AND METHODS
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Rats
Female F344 rats and athymic rnu/rnu rats were purchased from The National
Cancer Institute at Frederick (Frederick, MD). The animals were housed in a specificpathogen free facility at the University of New Mexico Animal Resource Facility. All
animal procedures were reviewed and approved by the Institutional Animal Care and Use
Committee and the Biosafety Committee at the University of New Mexico.

Bacteria
F. tularensis strains LVS and SCHU S4 were obtained from DynPort Vaccine
Company LLC (Frederick, MD). The original stock was expanded in Chamberlain’s
broth (Teknova; Hollister, CA) at 37oC for 48 h with gentle shaking and aliquots of the
culture were stored at -80oC without any preservative.

Vaccination and serum collection
Rats were lightly anesthetized with isoflurane (Abbott Laboratories; Chicago, IL)
and vaccinated s.c. between the shoulder blades with 5 x 107 CFU LVS in 100 l of PBS.
4 wks after vaccination, rats were euthanized by CO2 overexposure and immune serum
was collected and pooled. Normal serum was collected in a similar manner or purchased
from Charles River Laboratories (Wilmington, MA). Both normal and immune sera were
heated to 55 C for 30 min to inactivate complement, filter-sterilized through 0.22 µm
syringe tip-filter, (Millipore; Billerica, MA) and stored at -80 C.
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Purification of serum IgG and IgM
Serum IgG and IgM were purified using Melon Gel purification kit (Thermo
Scientific Pierce Protein Research; Rockford, IL) and Capture Select IgM affinity matrix
(BAC B.V.; Naarden, Netherlands) respectively, following the manufacturer’s
instructions with a few modifications. Briefly, normal and immune sera were diluted 10fold in PBS and then precipitated slowly with 50% ammonium sulfate overnight at 4oC.
The precipitate was separated from the supernatant by centrifugation at 3,000g for 20 min
and was resuspended in Melon Gel Purification Buffer for IgG purification or in PBS for
IgM purification. The suspensions were subsequently dialyzed 3 times against 300
volumes of Melon Gel Purification Buffer for IgG or PBS for IgM using Slide-A-Lyzer
dialysis cassette with 10kDa molecular weight cutoff (Thermo Scientific Pierce Protein
Research; Rockford, IL). IgG was purified from the dialyzed samples following the
manufacturer’s microcentrifuge spin-column protocol using a Melon gel volume that is
1.25 times the undiluted serum volume. IgM was purified using IgM affinity matrix resin
that is 0.5 times the undiluted serum volume. Before analyzing the purity and subsequent
treatment of rats, purified IgG and IgM were dialyzed against PBS as described above.
The concentration of total IgG and IgM was interpolated from a standard curve generated
with commercially available IgG and IgM of known concentration (Sigma-Aldrich; St.
Louis, MO) and the titer of anti-LVS IgG and IgM as well as contaminating Ab isotypes
was determined using LVS-specific ELISA as described below. The purity was analyzed
by 10% SDS polyacrylamide gel electrophoresis (Biorad; Hercules, CA).
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ELISA for anti-LVS Ab titer
Maxisorp 96-well microtiter plates (Nunc; Rochester, NY) were coated with 2.5-5
x 106 CFU/ml of heat-killed LVS in PBS overnight at 4°C. After blocking with 5% nonfat dry milk/PBS for 1 h at 37°C, 100 µl of rat serum were added in 2-fold serial dilutions
and incubated at 37°C for 1 h. Abs class and subclasses were detected by incubation with
horseradish peroxidase-conjugated goat Abs against rat IgG (Calbiochem; San Diego,
CA), IgG1, IgG2a, IgG2b, IgG2c, IgM and IgA (Thermo Scientific Pierce Protein
Research Products; Rockford, IL) for 45 min at 37oC. Between each step, the plates
were washed 5 times with 0.05% Tween 20/PBS. The plates were developed with a
solution of 3, 3', 5, 5'-tetramethylbenzidine (TMB) and the reaction was stopped with
1.8N H2SO4 and the optical density (OD) was read at 450nm. Ab titer was defined as
the reciprocal of the highest dilution of immune serum that had a mean OD value that is
at least 3 standard deviations higher than the mean OD of normal serum at the same
dilution.

Passive immunization and intratracheal challenge
Rats were passively immunized by i.p. injection of 250 l of serum, unless
otherwise indicated in selected experiments. Purified IgG and IgM was used in some
experiments; the volume given contained the equivalent amount of LVS-specific IgG as
in 250 µl of LVS-immune serum. 24 h after passive immunization, rats were infected i.t.
as described previously (48)(73). Briefly, rats were immobilized on an inclined platform
(Alpha Lab Supply; Albuquerque, NM) and intubated with a 20-gauge i.v. catheter
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(Terumo Medical Products; Somerset, NJ) with the help of a small animal laryngoscope
with a fiber optic light source (Penn-Century, Inc; Philadelphia, PA). In some
experiments 50l inoculum pre-mixed with self-illuminating quantum dots (Zymera; San
Jose, CA) was delivered using a blunt-ended needle and followed by 50l of
Coelenterazine and a burst of >500l of air to ensure the delivery of the inoculum. The
infected rats were imaged in vivo using the IVIS 100 Optical Imaging System (Caliper
Life Sciences; Hopkinton, MA). The health of the infected animals was monitored daily
along with weight loss and survival. The clinical scores of infection were assigned as
follows: 0 = active, bright and alert, responsive to handling; 1 = slight lethargy and
weight loss; 2 = decreased responsiveness to handling, clear piloerection, more
pronounced weight loss; 3 = definite decreased activity, ruffled coat, rapid and shallow
breathing, hunched posture, eyes half closed and may have porphyrin secretion; and 4 =
inactive and unresponsive to handling, weak and/or ataxic, severe weight loss, eyes
completely closed with a large amount of porphyrin secretion. Animals that succumbed
to infection were given a maximum score of 4.

Bacterial burden analysis
To quantify the deposited bacteria, lungs were aseptically removed 1 h after
infection and homogenized in PBS using a hand-held or multi-sample homogenizer fitted
with disposable plastic homogenizing probes (Omni International; Marietta, GA). Lung
homogenates were plated neat or at appropriate dilutions onto selective cysteine heart
agar plates with 5% rabbit blood, 100U/ml penicillin G, and 100U/ml polymyxin B
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(Remel; Lexena, KS) and bacterial colonies were quantified 4-5 days later using Qcount
(Spiral Biotech; Bethesda, MD). A similar procedure was followed to determine the
bacterial burden in lungs, spleen, and liver over the course of infection. When no
organism was found, a value equal to the limit of detection was used to calculate the
mean bacterial burden.

Histopathological evaluation
Following i.t. challenge, rats were euthanized by i.p. injection of 150l of
Sleepaway (Fort Dodge Animal Health; Fort Dodge, IA) (>100mg/kg) on day 1, 3, 5, 7,
10, 14, and 21 post-challenge. Lungs were removed from the thorax en bloc and inflated
with 10% neutral buffered formalin (NBF) via a tracheal cannula. Lungs, spleen, liver,
and tracheo-bronchial lymph nodes were fixed in 10% NBF for 24-72 hours and
subsequently trimmed for paraffin embedding. Paraffin-embedded tissues were sectioned
at 5 µm and stained with hematoxylin and eosin for histological analysis by a board
certified veterinary pathologist. Lesions were graded in a blinded manner on a semiquantitative scale based upon the severity and distribution of lesions (minimal = 1, mild =
2, moderate = 3, and marked = 4).

In vivo T-cell depletion and flow cytometry
The hybridoma clones OX-8 (mouse anti-rat CD8; IgG1), OX-38 (mouse anti-rat
CD4; IgG2a), 55-6 (mouse anti-HIV-1 gp120; IgG2a) were obtained from European
Collection of Cell Cultures (Salisbury, United Kingdom) and TS2/18.1.1 (mouse anti29

human CD2; IgG1) was from American Type Culture Collection (Manassas, VA).
Ascites fluids were generated in female ICR SCID mice and the IgG concentrations were
determined by high-performance liquid chromatography (Taconic; Albany, NY). For
CD4 T cell depletion, rats were injected i.p. with 5mg/kg of CD4 T cell-depleting Ab
OX-38 or isotype control Ab 55-6 for five consecutive days and then 1mg/rat twice a
week. For CD8 T cell depletion, 1mg/rat of CD8 T-cell depleting Ab OX-8 or isotype
control Ab TS2/18.1.1 Abs were administered once a week. One week after the start of
Ab treatment, the depletion efficiency was confirmed by flow cytometric analyses of
PBMCs collected by lateral tail vein bleed. In addition, the effect of CD4 T cell
depletion on the population of NK cells, B cells, and CD8 T cells in the spleen, liver, and
blood was examined. Rats were euthanized by CO2 overexposure and exsanguinated by
cutting the inferior vena cava. Blood collected from the chest cavity was mixed with an
equal volume of PBS supplemented with 50U/ml of heparin and layered over
Lympholyte-M density separation medium (Cedarlane; Burlingtion, NC) following
manufacturer’s instructions. The lymphocytes were collected at the interface of the
density gradient medium. To isolate splenocytes, spleens were homogenized between
ground glass slides and passed through 70µm nylon screen (BD Biosciences; San Jose,
CA). To isolate liver cells, the right lobes were homogenized through a 200-gauge
stainless steel mesh, resuspended in 40% Percoll and layered over a 70% Percoll solution.
The samples were centrifuged at 836 x g for 20 min. at 4˚C without break. Cells were
harvested from the Percoll interface. All the cell preparations were treated with RBC
lysis buffer (0.15M NH4Cl, 1mM KHCO3, 0.1mM Na2 EDTA) and washed with PBS
and resuspended in RPMI-10 (RPMI 1640 medium supplemented with 10% heat30

inactivated fetal bovine serum, 1 mM non-essential amino acids, 1 mM L-glutamine, 1
mM sodium pyruvate ) before staining. Cells were stained with biotinylated anti-CD8b
(mouse IgG1, , clone 341) and anti-CD161a (mouse IgG1, , clone 10/78), fluorescein
isothiocyanate (FITC)-conjugated anti-CD45R (mouse IgG2b, , clone HIS24) and
allophycocyanin (APC)-conjugated anti-CD3 (mouse IgM, , clone iF4) Abs from BD
Biosciences (San Jose, CA) and phycoerythrin (PE)-conjugated anti-CD8b (mouse IgG1,
, clone eBio341) and FITC-conjugated anti-CD4 Abs (mouse IgG2a, clone OX-35) Abs
from eBiosciences (San Diego, CA). Biotinylated cells were detected using peridininchlorophyll-protein (PerCP)-conjugated streptavidin (Biolegend; San Diego, CA).
Before staining the cells, non-specific Ab binding was blocked by incubating with antirat CD32 (mouse IgG1, , clone D34-485) according to the manufacturer’s instructions
(BD Biosciences; San Jose, CA). Appropriate isotype controls were used. The stained
cells were fixed in 0.5% paraformaldehyde and analyzed by flow cytometry on a FACS
calibur (BD Immunocytometry Systems; San Jose, CA). The flow cytometry data was
analyzed using Winlist (Verity; Topsham, ME).

Lymph node harvest and staining
Rats were euthanized with CO2 and lung-associated lymph nodes (LALNs) were
excised in to staining buffer (2% FBS, 0.2mM EDTA in PBS) before being homogenized
between ground slides. Mononuclear cells were isolated by ficoll density gradient
centrifugation (GE Healthcare, Waukisha, WI). Viable cells were enumerated by trypan
blue exclusion method and 1 x 106 cells per sample were stained in the same manner as
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described above. Abs used were APC-conjugated anti-CD3 (mouse IgM, , clone iF4),
PerCP-conjugated anti-RT1B (mouse IgG1, , clone OX-6) from BD Biosciences, APCconjugated anti-CD45RA from Biolegend (mouse IgG1, , clone OX-33) and PEconjugated anti-CD103 from eBiociences (mouse IgG1, clone OX-62). CD3+ cells were
designated as T cells while B cells were CD3- CD45RA+ RTIB+ and DCs were CD3CD45RA- RTIB+ CD103+.

Intracellular bacterial growth assay
Peripheral blood from naïve F344 rats was collected in to an equal volume of PBS
with 50U/ml of heparin. Mononuclear cells from the blood were enriched using
Lympholyte-M density separation medium according to the manufacturer’s instructions
(Cedarlane, Burlington, NC). Cells were enumerated by trypan blue exclusion method
and 2.5 x 105 cells were plated per well and incubated overnight at 37 C. SCHU S4 was
opsonized in RPMI-10 with heat-inactivated NRS or IRS for 20 min at 37 C by shaking
and added to triplicate wells at a multiplicity of infection of 10. The final serum volume
per well was 0.1%. After 2h, cells were pulsed with 50g/ml of gentamicin for 45-60
min and washed 3 times with warm PBS before adding RPMI-10 and incubated till the
harvesting point. At the indicated time points (~4 and 24 h) after infection, cells were
lysed with 0.1% sodium deoxycholate and serial dilutions of the lysates were plated on
chocolate agar plates (Remel, Lenexa, KS) to determine the intracellular bacterial load.
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Luminex analysis
Cytokine concentrations in the tissue homeogenate supernatants were measured
using Ab-linked beads that recognize 13 different cytokines (Invitrogen; Carlsbad, CA &
Millipore; Billerica, MA) and a Luminex 100 reader (Luminex Corporation; Austin, TX).
The raw data were analyzed with StatLIA statistical analysis program (Brendan
Scientific; Carlsbad, CA).

Blood chemistry
Blood samples were collected from rats sacrificed at 7 days p.i. with SCHU S4.
Sera were collected and filter-sterilized using 0.2m syringe filters. Sterility was
confirmed by plating undiluted serum samples on cysteine heart agar plates with 5%
rabbit blood and selective antibiotics. Sera were analyzed for blood urea nitrogen (BUN)
and alanine aminotransferase (ALT) at Tricore Reference Laboratories (Albuquerque,
NM).

IFN ELISPOT assay
IFN secreting cells in the LALNs of SCHU S4- and mock-infected rats were
estimated on days 3, 5, and 7 p.i. using an ELISPOT assay by following the
manufacturer’s instructions (Mabtech, Cincinnati, OH). Briefly, cell culture plates were
coated with 1.5 µg/well of monoclonal Ab specific for rat IFN in PBS and incubated
overnight at 4 ˚ C. Excess Ab was washed away and the plate was blocked with RPMI33

10 for at least 30 min at room temperature before washing the plate again and adding 2.5
x 10 5 single cell suspensions of LALN in 250 µl of RPMI-10 per well without any Ags
for stimulation. After overnight incubation at 37 ˚ C, the plates were washed and the
biotinylated detection Ab was added to incubate the plate at room temperature for 2 h.
Spots were visualized using streptavidin-alkaline phosphatase and BCIP (5-bromo-4chloro-3-indolyl-phosphate)/ NBT (nitro blue tetrazolium) as substrate. The spots were
enumerated using ViruSpot reader (Cell Technology, Mountain View, CA). Mockinfected mice did not produce any spots while wells with cells stimulated with
Conconavalin A (Sigma-Aldrich, St. Louis, MO) served as positive controls.

TdT-mediated dUTP-biotin nick end labeling (TUNEL) staining
Apoptotic cells in the tissue sections were detected by TUNEL of cleaved doublestrand DNA using ApopTag peroxidase in situ apoptosis detection kit (Millipore,
Billerica, MA) following manufacturer’s instructions. Briefly, deparaffined and
rehydrated tissue sections were treated with 3% hydrogen peroxide to quench the
endogenous peroxidases and subsequently permeabilized with proteinase K. Sections
were developed with diaminobenzidine after sequential treatment with TdT and antidigoxigenin conjugate.

34

Statistics
Kaplan-Meier survival curves were analyzed by log-rank test and SCHU S4
burden following multiple serum treatments was analyzed by two-way ANOVA. Total
cell populations from the tissues of isotype control-treated and CD4-depleting Ab-treated
animals were compared using two-tailed unpaired t test. These and other analyses were
performed using GraphPad Prism version 5.01 software (GraphPad Software; San Diego,
CA) as described in the figure legends. SCHU S4 growth kinetics in experiments with
single prophylactic serum treatment were analyzed by fitting two-way ANOVA with
interaction using general linear model in SAS (SAS Institute Inc.; Cary, NC).
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CHAPTER 4: ANTIBODIES CONTRIBUTE TO EFFECTIVE VACCINATION
AGAINST RESPIRATORY INFECTION BY TYPE A FRANCISELLA
TULARENSIS STRAINS
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Summary
Pneumonic tularemia is a life-threatening disease caused by inhalation of the highly
infectious intracellular bacterium Francisella tularensis. The most serious form of the
disease associated with the type A strains can be prevented in experimental animals
through vaccination with the attenuated Live Vaccine Strain (LVS). The protection is
largely cell-mediated, but the contribution of Abs remains controversial. We addressed
this issue in a series of passive immunization studies in Fischer 344 (F344) rats.
Subcutaneous LVS vaccination induced a robust serum Ab response dominated by IgM,
IgG2a and IgG2b Abs. Prophylactic administration of LVS immune serum or purified
immune IgG reduced the severity and duration of disease in naïve rats challenged
intratracheally with a lethal dose of the virulent type A strain SCHU S4. The level of
resistance increased with the volume of immune serum given, but the maximum
survivable SCHU S4 challenge dose was at least 100-fold lower than that shown for LVS
vaccinated rats. Protection correlated with reduced systemic bacterial growth, less severe
histopathology in the liver and spleen during the early phase of infection and bacterial
clearance by a T cell-dependent mechanism. Our results suggest that treatment with
immune serum limited the sequelae associated with infection, thereby enabling a
sterilizing T cell response to develop and resolve the infection. Thus, Abs induced by
LVS vaccination may contribute to the defense of F344 rats against respiratory infection
by type A strains of F. tularensis.
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Introduction
Pneumonic tularemia is a highly debilitating disease caused by the gram-negative
coccobacillus Francisella tularensis. Strains classified under subspecies tularensis (type
A) are the most virulent and pose the biggest challenge from a clinical perspective (41).
The mortality rate of pneumonic tularemia caused by the type A strains has been
estimated to exceed 30% in untreated patients (31). Prophylactic vaccination is the best
countermeasure and there is good historical evidence that pneumonic tularemia can be
prevented by vaccination with the attenuated F. tularensis Live Vaccine Strain (LVS)
(42). However, LVS is unlikely to be licensed for mass vaccination because the
mechanism of attenuation has not been defined. Due to the potential of a major public
health threat, there is an urgent need to understand the protective mechanisms associated
with an effective immune response so that novel vaccines can be developed.
Protective immunity against F. tularensis infection is usually attributed to an
effective T cell response. However, F. tularensis has a significant extracellular phase,
which makes it accessible to humoral immune responses (154). Indeed, there is ample
evidence that B cells and Abs are necessary for mice to develop their natural resistance to
primary and secondary LVS infections. Purified lipopolysaccharide (LPS) from LVS
induced a population of B1-a cells within 2-3 days of administration that protected mice
against intraperitoneal (i.p.) LVS challenge (156-158)(181-183). Consistent with these
results, µMT mice lacking mature B cells exhibited increased susceptibility to primary
intradermal (i.d.) LVS infection and delayed bacterial clearance (159, 160). µMT mice
were also more susceptible to secondary i.p. LVS infection and this defect was corrected
by reconstitution with LVS primed B cells (132). The contribution of Abs has been
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addressed repeatedly in passive immunization experiments, which showed that immune
serum from humans and mice vaccinated with live or inactivated LVS protected naïve
mice against challenges with LVS or other low virulence strains given by a variety of
routes (149, 151, 161-164). The dominant Ab response was directed at LPS, but Abs
against protein antigens have also been found (160, 165-167). Monoclonal Abs specific
for LPS or the outer-membrane protein FopA provided significant protection against LVS
challenge when given either prophylactically (168) or therapeutically (168). Together,
these results suggest that Abs contribute towards effective control of attenuated or low
virulence F. tularensis strains.
It has been much more difficult to demonstrate Ab-mediated protection against
type A strains in mice (152, 168, 169), even though they express most of antigens
recognized by LVS immune serum (161). This is not surprising given the historical
difficulties in generating protective immunity against type A strains in this animal model
(170). However, Ray et al. recently showed that oral LVS vaccination protected mice
against a pulmonary SCHU S4 challenge in an Ab-dependent manner (44). Klimpel et al.
also reported a similar finding using immune serum from mice cured of a lethal i.n.
SCHU S4 infection with levofloxacin in a passive immunization model (153). Thus, the
protective effects of Abs appear not to be restricted only to low virulence strains but may
also contribute to the protection against highly virulent type A strains.
To further characterize the mechanism of Ab-mediated protection, we utilized the
recently characterized Fischer 344 (F344) rat model (48). Since F344 rats developed
much stronger resistance to respiratory SCHU S4 challenge after LVS vaccination than
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previously observed in mice, we speculated that Abs may provide better protection in this
model and allow us to define their protective mechanism more thoroughly. We now
show in a passive immunization model that serum Abs from LVS-vaccinated rats
conferred protection against a lethal intratracheal SCHU S4 challenge. Protection
correlated with reduced systemic bacterial growth and less severe histopathology during
the early phase of infection and bacterial clearance by a T cell-dependent mechanism.
Thus, Abs contribute to but are not sufficient for the effective control of respiratory
infections by fully virulent type A strains. Our studies provide valuable insights into the
protective mechanisms of Abs that will guide future development of tularemia vaccine
candidates.
Results
Development of serum Ab response after s.c. LVS vaccination
We showed previously that Fischer 344 rats cleared a vaccine inoculum of 5 x 107
LVS within two weeks of subcutaneous vaccination and were protected when challenged
two weeks later with SCHU S4 i.t. (48). To determine the Ab response over this 4-week
period, the serum concentration of LVS-specific IgM, IgG, and IgA were measured.
Subcutaneous LVS vaccination induced a robust serum IgM and IgG response in F344
rats (Figure 2). The average IgM and IgG titers after 7 days were 1:64,000 and 1:16,000,
respectively. The IgM titer peaked one week later at 1:32,000 and declined thereafter.
The IgG titer remained relatively stable at 1:16-32,000 over the 4-week period. Serum
IgA was detected in all vaccinated rats, but the titer never exceeded 1:800 (data not
shown).
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Figure 2. Subcutaneous LVS vaccination induces a robust IgM and IgG serum Ab response. F344 rats (n =
3) were vaccinated s.c. with 5 X 107 CFU of LVS. Sera were collected on days 7, 15, 21, and 28 d postinoculation and the total LVS-specific IgM, IgG and IgA Ab titer was determined for each rat by ELISA
using heat-killed LVS as the capture antigen. Ab titer was defined as the reciprocal of the highest dilution
of immune serum that had a mean OD value that is greater than 3 standard deviations above than the mean
OD of normal serum at the same dilution. The data show the geometric mean ± SD.
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Passive immunization with immune serum protects F344 rats against pneumonic
tularemia
To determine whether LVS-specific serum Abs can protect F344 rats against i.t.
SCHU S4 challenge, naïve F344 rats were treated prophylactically with immune rat
serum (IRS) and then challenged i.t. with SCHU S4. Immune sera were pooled from
several F344 rats 28 days after LVS vaccination when no trace of LVS could be detected
systemically. The predominant Abs were IgM, IgG2a and IgG2b and the titers of IgG1,
IgG2c and IgA were at least 10-fold less (Figure 3). Naïve F344 rats were treated i.p.
with an arbitrary volume of 250 µl IRS, a volume which constituted ~7 % of the total
serum volume in a recipient F344 rat weighing ~150 g. 24 h after serum transfer, the
passively immunized rats were challenged i.t. with a small but lethal dose of ~250 CFU,
which was selected intentionally to reduce the threshold required to detect any protective
effect brought about by the LVS-immune serum. Rats treated with normal rat serum
(NRS) and LVS-vaccinated rats were used as negative and positive controls, respectively.
All rats were monitored for survival, weight loss, and clinical signs for 5 weeks.
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Figure 3. Ab composition in the immune serum used for passive immunization. F344 rats (n = 3-4) were
vaccinated s.c. with 5 x 107 CFU of LVS. Sera were collected 28 d post-vaccination and analyzed by
ELISA for the presence of LVS-specific Abs of the indicated isotypes and subclasses using heat-killed LVS
as the capture antigen. Ab titer was defined as described in Fig. 1. The data represent the geometric mean
± SD of samples combined from two independent experiments.
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Figure 4. Passive immunization with IRS protects naïve rats against a lethal i.t. SCHU S4 challenge.
Groups (n=6) of LVS-vaccinated rats and naïve F344 rats were treated i.p. with 250 µl of heat-inactivated
NRS or IRS and then challenged i.t. 24h later with 240 CFU of SCHU S4. The challenge dose represents
the actual lung deposition determined within 1 h of infection. The infected rats were monitored daily for
(A) weight, (B) clinical signs, and (C) survival. In panel A, the results are presented as a percent relative to
the body weight measured 24h before challenge. A value of 100% indicates no weight change and points
above and below 100% represents weight gain and loss, respectively. In panel B, the disease severity was
scored based on the criteria described in Materials and Methods. Data represents the average of all
survivors in each group ± SD.
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The first indication of illness in the NRS-treated rats was a slight weight loss and
decreased alertness 3-4 days post-infection (p.i.). The disease progressed very quickly
over the next 48-72 h and was characterized by rapid loss up to 30% of body weight
(Figure 4A) and development of severe lethargy, ruffled coat, eyelid ptosis, and hunched
posture (Figure 4B). At the peak of disease severity, the rats were extremely weak and
unresponsive and their eyes were completely closed surrounded by a large amount of
ocular discharge. Most infected rats died within 2 weeks of infection (Figure 4C).
Although the IRS-treated rats exhibited some of the early signs of infection, weight loss
occurred more gradually and rarely exceeded 10% of the initial body weight. All signs of
illness resolved within 2 weeks of infection and the rats remained outwardly healthy for
the remaining 2-3 weeks of monitoring. LVS vaccinated rats never lost weight or
exhibited any overt signs of disease. In five independent experiments, at a SCHU S4
challenge dose of 218-240 CFU, 27 of 29 rats treated with IRS survived while 29 of 30
NRS-treated rats died (Table II). These results suggested that serum Abs are capable of
mediating protection against a lethal respiratory SCHU S4 infection.
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Table II. Summary of survival results of F344 rats challenged intra-tracheally with SCHU S4 after
prophylactic treatment with 250 µl of serum.

SCHU S4
Challenge
Dose (CFU)a
130
218-240b
360
727
1496
3525
10083

Immune Rat Serum
Survival ratio
MTDc
(No.
(days)
alive/total)
6/6
27/29
11
5/6
12
5/6
14
1/6
11
0/6
13
0/6
10

a

Normal Rat Serum
Survival ratio
MTD
(No. alive/total)
(days)

Bacteria recovered from the lungs 1 h after infection.
Includes 5 separate experiments using a challenge dose within this range.
c
Mean time to death
b
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1/5
1/30
0/5
0/6

7
9
8
7

0/6
0/6

8
4

Purified IgG is sufficient for protection against SCHU S4 infection
To verify that LVS-specific Abs were responsible for the serum-mediated
protection, IgG and IgM were purified from normal and immune sera. The purification
process reduced the titer of contaminating Ab isotypes to < 1:100 and removed most
contaminating proteins, except for a prominent 75 kDa protein in the purified IgG
fraction that has not been identified (Figure 5A and B). For passive immunization, F344
rats were injected with an amount of purified IgG and/or IgM that is equivalent to that
contained in 250 µl of serum. Similar to IRS, purified immune IgG provided significant
protection against i.t. SCHU S4 challenge (Figure 5C). In contrast, purified immune IgM
offered no protection and the treated rats succumbed to SCHU S4 infection at the same
time as rats treated with normal serum. These results indicated that LVS-specific IgG is
the principal protective component in the immune serum. Since IRS and purified
immune IgG provided similar level of protection, IRS was used in all experiments
described hereafter.
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Figure 5. Passive transfer of purified LVS-immune IgG, but not IgM, protects naïve rats against a lethal i.t.
SCHU S4 challenge. IgG and IgM were purified from pooled normal rat serum (NRS) and immune rat
serum (IRS) collected 28 days after s.c. LVS vaccination. The purity of enriched IgG (A) and IgM (B)
preparations was analyzed by SDS/PAGE gels stained with Coomassie blue dye. IRG, immune IgG; NRG,
normal IgG; IRM, immune IgM; NRM, normal IgM. The titer of LVS-specific IgM, IgG, and IgA was
determined by ELISA as indicated in Figure 2 and the titer of contaminating Ab isotypes in the enriched
preparations was < 1:100. (C) Groups of 5 F344 rats were treated with an amount of purified IgG and IgM
that is equivalent to 250 µl of serum and challenged i.t. 1 day later with 810 CFU of SCHU S4. Survival
was monitored daily.
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Immune serum treatment of F344 rats limits SCHU S4 growth
Since IRS treatment provided significant protection against pulmonary SCHU S4
infection, we next investigated the effect of this treatment on SCHU S4 growth. IRStreated rats exhibited a pattern of SCHU S4 growth and dissemination that was
intermediate between the NRS-treated rats and the LVS-vaccinated rats. Bacterial
expansion in the first two days following infection was identical between the IRS- and
NRS-treated rats: in both groups, the number of lung bacteria increased to 107 CFU and
systemic dissemination to the liver and spleen had occurred in the majority of animals
(Figure 6). The two groups started to diverge on day 3 when fewer bacteria were
recovered from the IRS-treated rats. The bacterial burden in NRS-treated rats peaked on
day 7 p.i. shortly before they died with 8x108 CFU in the lungs, 4x108 CFU in the liver,
and 2x107 CFU in the spleen. In contrast, the bacterial burden in the IRS-treated rats
increased at a slower rate to peak on day 10 p.i. By day 14, the infection began to clear in
the IRS-treated rats and the bacterial load in all three tissues had dropped from their peak.
These results suggest that IRS may contribute to protection of naïve F344 rats by limiting
bacterial growth and facilitating development of an immune response that eventually
cleared the infection.
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Figure 6. IRS-treated rats exhibit a pattern of SCHU S4 growth intermediate between NRS-treated rats and
LVS-vaccinated rats. LVS-vaccinated F344 rats and naïve rats treated with 250 µl of heat-inactivated
normal rat serum (NRS) or heat-inactivated immune rat serum (IRS) were challenged i.t. 1 d after serum
treatment with 260 CFU of SCHU S4. 3-4 rats were euthanized from each group on days 0, 1, 3, 5, 7, 10,
14, and 21 post-challenge and to determine the total SCHU S4 burden in the lungs, spleen, and liver. The
numbers of lung bacteria on day 0 reflects the actual lung deposition determined within 1 h of infection and
the dashed lines represent the limit of detection for each organ. Each data point represents mean ± SD.
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Protection by IRS is dependent on the SCHU S4 challenge dose and the volume of IRS
To further characterize the potency of IRS, titrations of the SCHU S4 challenge
dose and the IRS volume were performed. A single treatment with 250 µl of IRS
provided long-term protection to over 90% of naïve rats challenged with up to ~700 CFU
SCHU S4 (Table II). The mortality rate increased when the challenge dose was increased
to over 1.5 x 103 CFU and all of the infected rats died between 10 and 13 days after
challenge. There was little correlation between the challenge dose and the time-to-death.
The cumulative results from 7 independent experiments suggested that the i.t. LD50 of
SCHU S4 in F344 rats treated with 250 µl of IRS was in the range of 700 and 1500 CFU;
this is at least 100-fold less than the LD50 associated with s.c. LVS vaccination (48).
Reducing the IRS volume had a dose-dependent effect on the level of protection against a
fixed challenge dose. When the IRS volume was reduced to 25 µl, the treatment
prolonged the survival of rats challenged i.t. with 360 CFU by 4-5 days, but they
eventually succumbed to infection (Figure 7). All protective effects were eliminated
when the IRS volume was further reduced to 2.5 and 0.25 µl. Increasing the IRS volume
to 1 ml did not substantially delay disease onset, improve clinical signs, or accelerate
resolution compared to the 250 µl treatment (data not shown). Since the effectiveness of
a single IRS treatment may be limited by the availability of target organisms at or around
the time of administration, rats were given repeated IRS injections in an attempt to match
the increasing bacteria numbers due to proliferation over the course of infection. F344
rats were either treated with 250 µl of IRS once before SCHU S4 challenge or multiple
times on days -1, 3, 6, 9, and 12 relative to challenge. The total bacterial burden in the
lungs, spleen, and liver of rats was determined on days 3, 5, 7, 10, and 14 after challenge.
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As shown in Figure 8, multiple Ab treatments did not alter the general pattern of SCHU
S4 growth and dissemination compared to a single treatment (p > 0.05 for all three
organs).
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Figure 7. IRS-mediated protection is dose-dependent. Groups of F344 rats (n = 6) were treated i.p. with
the indicated volumes of heat-inactivated IRS and 1 d later challenged i.t. with 360 CFU of SCHU S4.
Four additional groups of rats were treated with the equivalent volumes of NRS. All but one rat treated
with 250 µl died by day 10 of infection.
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Figure 8. Multiple IRS treatments have the same effect on SCHU S4 growth kinetics as a single treatment.
Naïve F344 rats were either treated with a single dose of 250µl of heat-inactivated IRS 1 d before challenge
(day -1) or with multiple 250 µl doses on days -1, 3, 6, 9, and 12. One day after the first treatment, rats
were challenged i.t. with 420 CFU of SCHU S4. On the indicated days, the bacterial burdens in the lungs
and spleens and liver were determined from 3 rats per group. The dashed lines indicate the detection limit
for each tissue and each data point represents mean ± SD. There was no significant difference in the
bacterial burden between the two groups (p > 0.05).

55

Taken together, these results showed that a single IRS treatment was sufficient to
protect F344 rats against i.t. challenge of up to ~700 SCHU S4 organisms. This
protection required a minimum IRS volume of 250 µl and any amount beyond this
volume threshold given in a single or multiple treatments provided little additional
benefit.

Histopathology of serum-treated rats after i.t. challenge with SCHU S4
In order to determine how the IRS-treated rats survived a lethal pulmonary SCHU
S4 challenge despite an extremely high bacterial burden, we next evaluated whether IRS
treatment limited the histopathology in the infected tissues. Lung lesions in both IRSand NRS-treated rats were first detected on day 3 p.i., and consisted of neutrophilic and
histiocytic inflammation within alveoli, bronchioles, and bronchi, and in the perivascular
spaces of adjacent blood vessels. Over the next 4 days, the lung inflammation became
progressively more necrotizing in both exposure groups. Lung lesions severity was
similar in the IRS- and NRS-treated rats during the first 7 days p.i., after which time the
NRS-treated rats did not survive. For comparison, the lung lesions in LVS-vaccinated
rats were similar in nature and severity to the IRS- and NRS-treated rats during the first 5
days p.i., but gradually decreased in severity starting at day 7 p.i.
Lesions in the liver and spleen were first detected in the IRS- and NRS- treated
rats on day 3 p.i.. Splenic and hepatic lesions consisted of multifocal, random
neutrophilic and histiocytic inflammation on day 3 p.i., and frequently progressed to
necrotizing inflammation by day 5 p.i. In both the IRS- and NRS-treated rats, maximal
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hepatic and splenic lesion severity was achieved on day 5 p.i. However, the maximal
severity score for splenic and hepatic lesions in the IRS-treated rats was less than for the
NRS- treated rats. Furthermore, the lesion severity decreased for the IRS- treated rats by
day 7 p.i., but not for the NRS- treated rats. For comparison, in the vaccinated rats,
lesions were sparse to non-existent at all the time points examined (Figure 9A-F). These
results demonstrate that IRS treatment reduced the inflammation in tissues to which F.
tularensis is known to disseminate.
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Figure 9. IRS-treated rats develop less severe splenic inflammation than NRS-treated control rats at day 7
p.i. with SCHU S4. The spleens of LVS-vaccinated (LVS vac), or IRS- and NRS-treated rats were
examined histologically at day 7 after SCHU S4 challenge. The spleens of vaccinated rats were without
detectable lesions (A and B). The spleens of the NRS-treated rats exhibited nearly complete effacement of
the red pulp with neutrophilic and histiocytic inflammation (C and D), while the spleens of the IRS-treated
rats exhibited only multifocal neutrophilic and histiocytic inflammation in the red pulp (E and F). Arrows
point to paler appearing areas of inflammation in the splenic red pulp.
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T cells are critical for Ab-mediated protection
The importance of T cells in Ab-mediated protection was determined in T celldeficient athymic nude rats. Nude rats were derived from a heterogeneous genetic
background and have normal B cell function, but an increased NK cell population. Nude
rats were more resistant to SCHU S4 infection and lived 2-3 days longer than similarly
infected F344 rats. Prophylactic treatment with 250 µl of IRS significantly prolonged the
survival of infected nude rats by 3 days (p < 0.01) but all the infected animals died by
day 16 p.i. (Figure 10A). These results suggested that a T cell-independent mechanism
can temporarily modify the disease process, but T cells are critical for the long-term
protection associated with immune serum.
To determine the requirement for CD4 and CD8 T cells in passively immunized
F344 rats, we developed very effective in vivo depletion regimen using the anti-CD8 Ab,
OX-8, and the anti-CD4 Ab, OX-38. These Ab treatment regimens reduced and
maintained the peripheral blood CD4 and CD8 T cell populations to < 5 and < 1 % of
normal levels, respectively, over the course of infection. As shown in Figure 10B,
depletion of CD8 T cells completely abolished the ability of IRS to protect against SCHU
S4 challenge. Depletion of CD4 T cells had only a partial effect. This may be related to a
slight (<2-fold), but not statistically significant, increase in the total number of CD8 T
cells in the spleen, liver and blood; no difference in B cells (CD45R+) or NK cells
(CD161+) were observed (data not shown). Indeed, the mortality rate of rats depleted of
both CD4 and CD8 T cells was similar to the animals depleted of CD8 T cells alone.
Thus, these results suggest that CD8 T cells are essential for IRS to protect rats against
pulmonary infection with SCHU S4.
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Figure 10. IRS-mediated protection is dependent on T cells. (A) T cell-deficient athymic (RNu) nude rats
and immunocompetent Fischer 344 rats (n = 6 per group) were treated with 250µl of heat-inactivated IRS
or NRS and 1 day later challenged i.t. with 465 CFU SCHU S4. (B) Naïve F344 rats (n=5) were depleted
of CD4, CD8 or both CD4 and CD8 T cells by i.p. injection of depleting Abs OX-38 (CD4) and OX-8
(CD8). T cell depletion was maintained over the course of infection with additional treatments with
depleting Abs. The T cell-depleted rats were treated with 250µl of heat-inactivated IRS or NRS and 1 day
later challenged i.t. with 810 CFU of SCHU S4. The rats were monitored daily for survival and clinical
signs of illness.
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Discussion
It is widely accepted that tularemia vaccines such as LVS must induce a potent
cell-mediated immunity to be effective against highly virulent type A strains of F.
tularensis. LVS vaccination also induces a strong Ab response, but its role in protection
has not been thoroughly addressed. We now show that the serum Abs provided
significant protection against a lethal, respiratory SCHU S4 challenge in the F344 rat
passive immunization model. These results suggest that Abs may be an important
component in the overall defense against pneumonic tularemia.
We previously showed that the F344 rat is a good animal model for studying
human pneumonic tularemia (48). In the present study, F344 rats were vaccinated s.c. to
reproduce human vaccination by the scarification method currently used under the
Special Immunization Program at USAMRIID. Similar to humans vaccinated by
scarification (131, 132), the s.c. vaccinated rats developed a strong IgM and IgG response
within a week of vaccination. Further studies showed that only purified serum IgG but
not IgM mediated protection against i.t. SCHU S4 challenge in the rat. We have not
ruled out the potential contribution of IgA to protection, especially in the lungs or other
mucosal surfaces. In fact, the majority of humans (131, 132) and mice developed
positive serum IgA titers following scarification or i.n. vaccination, respectively. The
protective capabilities of IgA has been demonstrated repeatedly in vaccine studies with
IgA-deficient mice, which did not develop complete resistance against respiratory
infections with LVS (171, 172) and SCHU S4 (44). A significant amount of IgA was
also found in the immune mouse serum that passively transferred immunity against i.n.
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LVS infection (151). Thus, in addition to IgG, IgA may also play a role in protection
against respiratory tularemia caused by type A strains.
It has been suggested that the morbidity and mortality associated with pneumonic
tularemia is caused by the damage inflicted on the extrapulmonary tissues (173). An
extension of this idea is that control of bacterial dissemination and growth outside of the
lungs would offer considerable survival advantage. Our results are consistent with this
idea and suggest that passive immunization modified the course of acute infection by
enhancing the innate immune response to disseminated bacteria. The presence of LVSspecific Abs appeared to be most critical during the early phase of infection because IRS
failed to rescue infected rats when the treatment was delayed by 48 h (data not shown)
and increasing the amount of serum or the treatment frequency did not improve the level
of protection. IRS treatment had little, if any, quantitative or qualitative impact on the
bacterial burden and the histopathology in the lungs. Rather, the effect of IRS on
bacterial growth was most clearly observed in the infected liver and spleen. The liver is a
major site of F. tularensis colonization and replication and pneumonic tularemia is
associated with hepatocellular damage in multiple experimental animal models, including
the F344 rat (48, 173). Although the level of damage falls short of liver failure and may
be reversible, such damage may nevertheless compromise the liver's ability to perform
essential metabolic functions and to utilize its many innate immune mechanisms to
control systemic bacterial growth. In contrast, IRS treatment reduced the bacterial
burden and histopathology in liver and, in doing so, may have preserved more liver
functions in the infected rat. Similar passive immunization studies in mice with LVS
point to a process that involves Fc receptor and IFN and the liver is one of the
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richest sources of NK cells that are capable of producing IFN in response to F.
tularensis infection (111). This may also explain the ability of immune serum to delay
the death of athymic nude rats and mice, which express higher NK cell activity than wildtype animals. By controlling the rapid growth rate and dissemination of SCHU S4 and
limiting the pathological damage associated with infection, IRS may have enabled the
host to survive long enough to develop an effective T cell response that eliminated the
infection. Indeed, LVS-vaccinated rats with both F. tularensis-specific Abs and immune
T cells have the lowest bacterial burden and show the least histological changes
following SCHU S4 infection.
T cells are required for the long-term protective effects of passive immunization.
In the absence of T cells, IRS only delayed the death of athymic nude rats by several
days. CD8 T cells appeared to play a more critical role than CD4 T cells since depletion
of CD8 T cell rendered rats completely susceptible to SCHU S4 infection while only a
fraction of the rats depleted of CD4 T cells succumbed. A possible explanation for the
partial effect of CD4 T cell depletion is that the level of depletion may have been slightly
different for each rat and the survivors had more residual cells. It is also possible that
challenge dose varied slightly for each rat and the survivors were challenged with a lower
dose.
With the growing awareness of the importance of Abs for effective immunity
against pneumonic tularemia, new vaccine designs are beginning to incorporate Abs or
elements that induce stronger Ab responses. For example, Abs against LPS were used to
enhance antigen presentation by targeting inactivated LVS to Fc receptors on myeloid
cells (172,197, 198, 199,). Cholera toxin B and a LVS O-polysaccharide-tetanus toxoid
63

glycoconjugate (174) were used to induce a better Ab response to augment the cellular
immunity generated with inactivated or mutant LVS. Several groups have also used
protein microarrays (160, 165) and immunoproteomic approaches (166, 167) to identify
immunoreactive Abs in serum from humans and mice with previous exposure to F.
tularensis. In order to further improve these novel vaccine designs and to develop Abs
into potential ancillary therapeutic agents, it will be necessary to characterize the
protective response associated with any potential Ab candidate. The fact that F344 rats
were consistently protected by immune serum alone suggests that the F344 rat model will
be a valuable tool not only to test the protective effect of these Abs but also to
characterize their mechanism of protection.
In conclusion, our studies showed that LVS vaccination induced serum Abs that
were protective against a lethal respiratory SCHU S4 infection. The protective responses
defined in these studies provide valuable insights into the mechanism of Ab-mediated
protection and will help guide the rational design of novel tularemia vaccines that induce
not only a robust cellular immunity but also a strong humoral immunity.
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CHAPTER 5: PASSIVE IMMUNIZATION WITH LVS-SPECIFIC ANTIBODIES
CONTROLS INFLAMMATION AND ENABLES THE DEVELOPMENT OF
PROTECTIVE IMMUNITY AGAINST PULMONARY INFECTION BY
VIRULENT TYPE A STRAINS OF FRANCISELLA TULARENSIS
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Summary
Type A Ft strains cause fatal illness when infected by the aerosol route. The protective
mechanisms of Abs during pulmonary infection, hitherto unexplored, were studied using
the F344 passive immunization model. Naïve F344 rats were killed by lethal i.t. SCHU
S4 challenge when the Abs specific for Ft LPS were absent and also upon delaying
immune Ab administration for >48 h after infection. Opsonization with Abs significantly
increased SCHU S4 uptake by PBMCs and controlled their intracellular growth rate but
the bacterial numbers remained significantly high when the direct effects of Abs were
studied in vitro. IRS treatment in the SCHU S4 infected animals was associated with
reduced hyperinflammatory cytokine profiles, apoptosis, and injury in the sampled
tissues. In contrast to the NRS-treated rats where the immune cell viability and IFN
secretion was severely compromised in the LDLNs by 7 days p.i., IRS-treatment might
have enabled survival against both primary and secondary challenges against SCHU S4
by acting early in the infection to allow for timely and adequate development of adaptive
immunity. These studies offer several clues to explore the potential actions of Abs early
in the infection to alter the disease processes while providing scope for designing Abbased therapeutics to mitigate the severity associated with pulmonary tularemia.

Introduction
Type A strains of F. tularensis can endanger human lives when they infect the
airways due to their proven high infectivity and extreme virulence through this route of
exposure. The resulting illness can prolong for weeks in the absence of timely treatment
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with antibiotics and may lead to case fatalities as exemplified by the outbreaks of
pneumonic tularemia on Martha’s Vineyard (175, 176). The development of
prophylactic and therapeutic medical interventions is therefore necessary to minimize
fiscal and human losses. Since vaccines represent cheap, yet potent, means of
circumventing the adverse effects of pulmonary infection with SCHU S4, delineating the
interplay between the pathogen and host as well as characterizing the protective immune
components capable of subverting the damage inflicted during inhalational tularemia are
essential for designing effective vaccines.
Three distinct virulence attributes are commonly encountered during infection
with type A F. tularensis. First, the pathogen multiplies unbridled, to very high levels at
the infection site and in all the organs to which it disseminates to adversely impact their
normal functioning (43). Second, a sepsis-like condition, characterized by dysregulated
host immune response with elevated cytokines and chemokines, ensues a few days after
infection. Sepsis with accompanying manifestation of inflammatory mediators has been
reported in both murine models and humans (52, 53, 91, 177-181). Finally, extensive
tissue damage and multiple organ failure with concomitant death of innate and adaptive
immune cells, renders infection with type A F. tularensis, life-threatening. Specimens
from autopsy samples of humans who succumbed to type A F. tularensis showed
extensive necrotizing lesions in the lungs, lymph nodes, kidneys, livers, and spleens
(182). Plasma samples consistently show significantly high levels of liver enzymes and
lactate dehydrogenase, which is indicative of tissue damage (181, 183-185). Severe loss
in liver macrophage viability and T cell destruction in the thymus and T-dependent
regions of peripheral lymphoid tissues of SCHU S4-infected animals have been reported
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(52, 186). Hence the immune responses targeting the pathogen may not only have to be
effective in eliminating the pathogen, but also be balanced at the same time to prevent the
collateral damage from becoming fatal.
A measured host response that enables the timely development of adaptive
immunity that can clear SCHU S4 may hence be critical for survival. The protective role
of Abs, which has remained ambiguous, was addressed through the development of
passive immunization model using F344 rats. As described in Chapter IV, LVS-specific
Abs provided long-term protection in F344 rats infected with a lethal dose of SCHU S4
with the help of CD8 T cells. Even in the absence of T cells, Abs significantly prolonged
the MTD. The current chapter aims to identify the potential mechanism(s) through which
Abs prove to be beneficial to the host. This chapter describes the investigations in to the
protective actions of Abs. The direct role of Abs in arresting SCHU S4 growth in
infected rat PBMCs was probed. Furthermore, the immunomodulatory effect of LVSimmune Abs administered both before and after pulmonary SCHU S4 infection was
studied. The kinetics of adaptive immune response development as well as population
dynamics of different cells which potentiate these adaptive immune responses were
examined in the context of LALNs.
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Results

SCHU S4 opsonization with IRS enhances phagocytosis and controls its intracellular
growth rate
Our previous experiments suggested that the SCHU S4 growth kinetics in vivo
(Figures 6 and 8) could be influenced by factors other than immune Abs, the direct
effects of Abs on intracellular SCHU S4 growth kinetics were studied in the rat PBMCs
in order to gain further insight in to protective actions of IRS. Compared to NRS,
opsonization with IRS significantly enhanced the SCHU S4 uptake when the intracellular
bacteria was plated and enumerated ~4hrs after infection (Figure 11A). As little as 0.1%
of IRS added to PBMCs consistently enabled phagocytosis of SCHU S4 by at least a log
higher than NRS. 1 d later the intracellular SCHU S4 increased to > 104 CFU in both the
treatments and the IRS-treated wells still harbored significantly higher bacteria (Figure
11A). However, when the change in intracellular SCHU S4 between the initial and final
time points was calculated, the fold increase in IRS-treated wells was significantly lower
than NRS treatments (Figure11B). These results therefore suggest that enhanced
phagocytosis by IRS results in decreased intracellular multiplication of SCHU S4.
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Figure 11. Opsonization with IRS enhances phagocytosis while limiting the intracellular SCHU S4 growth .
Rat PBMCs were isolated from blood collected from naïve rats through lateral tail vein bleeding. Isolated
PBMCs were plated in triplicates and infected with NRS- or IRS-opsonized SCHU S4 (0.1% serum; 10
MOI) using the gentamicin protection assay described in Materials and Methods. PBMCs were lysed at the
indicated time points and the bacteria were enumerated after making appropriate dilutions and plating the
lysates. Data shown in (A) are mean +/- SD of results from triplicate wells and are representative of four
independent experiments of similar design. In (B), the fold-increase for each treatment was calculated by
dividing the average CFU of the triplicates at 24 h p.i. by the average CFU of the triplicates at 4 h p.i. The
results of four independent and similar experiments were combined and represented as mean +/- SEM.
Asterisks denote statistically significant differences according to one-tailed student’s t-test (*, p<0.05; ***,
p<0.0001).
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Multiple, but not single, IRS treatments protect naïve rats against i.t. challenge with a
high dose of SCHU S4
Experiments described previously showed that IRS-treated rats harbor >107 CFU
of SCHU S4 till 2 weeks p.i. in their reticuloendothelial organs (Figures 6 and 8). This
high level of bacteria is lethal to a naïve rat. Furthermore, multiple IRS treatments did
not reduce the bacterial burden in the sampled tissues significantly (Figure 8). In
addition, the gentamicin protection assay with rat PBMCs showed that IRS-mediated
uptake failed to decrease intracellular SCHU S4 burden since the bacterial numbers
remained significantly high 24 h p.i. Since these data suggested that IRS mediates
protection through mechanisms in addition to controlling bacterial growth, we wanted to
see if repeated Ab administration protects naïve F344 rats against i.t. challenge with a
high dose of SCHU S4. One group of naïve F344 rats were treated once with 250µl of
IRS 24h before challenge while another group received additional 250µl-IRS treatments
on days 1, 2, 3, 5, 7, 9, and 11 p.i. These groups were challenged i.t. with a high dose of
SCHU S4 while the other two groups given a single treatment with 250µl of NRS or IRS
and challenged with a low-dose SCHU S4 challenge served as controls. Multiple IRS
treatments significantly enhanced the survival against a high-dose SCHU S4 challenge
(~66% survival) (Figure 12). Moreover, the MTD was significantly delayed in the 2 rats
that died from this group. In contrast, in the group that received a single prophylactic
IRS treatment, 5 out 6 rats succumbed to infection. These results therefore demonstrate
the benefit of repeated IRS treatments in enhancing protection even against high SCHU
S4 challenge doses.
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Figure 12. Multiple IRS treatments provide protection to naïve F344 rats against a high dose i.t. SCHU S4
challenge. Groups (n=6) of naïve F344 rats were given a single treatment with 250µl of heat-inactivated
NRS or IRS 24h before challenge (-1) or multiple 250µl IRS-treatments on days -1 and 1, 2, 3, 5, 7, 9, and
11. One day after the first treatment, the animals were challenged i.t. with the indicated dose of SCHU S4
and monitored daily for survival.
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Post-challenge treatment with IRS rescues F344 rats from i.t. SCHU S4 challenge
Experimental data presented so far showed that prophylactic IRS treatment
provided protection against i.t. SCHU S4 challenged. To determine if the delayed Ab
treatment affected the survival of SCHU S4-infected animals, naïve F344 rats were
challenged i.t. with a lethal dose of SCHU S4 and different groups were treated with
250l of IRS at 1, 24, 48, 72, and 96 h post-infection. F344 rats prophylactically treated
with IRS served as positive controls. Rats that received IRS at 1, 24, and 48 h after
SCHU S4 challenge were significantly protected (Figure 13A). Only 1 rat died from the
group which received IRS ~1h after challenged. When the IRS treatment was delayed
beyond 48h, none of the rats were protected (72 and 96h p.i.). It must be mentioned that
the i.t. infection becomes bacterimic by 48 h after infection (data not shown). Rats in
these groups also showed sharp weight loss. In the rats that survived the lethal challenge,
the weight loss was distinctly more in the rats injected with Abs 48 h p.i. than those
animals which received Abs earlier (-24, 1, and 24h p.i.). As a proof of therapeutic
potential of LVS-immune Abs, these results show that IRS can provide protection when
administered up to 48h post-challenge and any further delay in IRS treatment
significantly compromises the survival.
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Figure 13. Post-challenge treatment with IRS for up to 48 h provides protection. Groups (n=4) of naïve
F344 rats were challenged i.t. with 428 CFU of SCHU S4 treated with 250l of heat-inactivated IRS or
NRS at the indicated time points. The challenge dose represents the actual lung deposition determined 1h
after infection. The infected rats were monitored daily for survival (A) and weight loss (B). A value of
100% indicates no weight change, and points above and below 100% represent weight gain and loss,
respectively. Data represents mean +/- SD of all the survivors.
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IRS-treated rats show decreased inflammation profile and damage in SCHU S4 target
organs
In vitro and in vivo bacterial growth data as well as survival results of postchallenge IRS treatment suggested additional factors apart from control in bacterial
dissemination contributed towards protection of IRS-treated rats. To this end, a series of
experiments were conducted to ascertain the potential factors contributing towards
survival during a lethal i.t. pulmonary infection. The cytokine and chemokine profiles in
the sera and lung, spleen, and liver homogenates of SCHU S4-infected rats at various
time points were evaluated by multi-analyte analysis. At the early time points (2-3 days
p.i.), the cytokine levels in the IRS-treated rats were not significantly different from
NRS-treated rats in any tissue homogenates, which suggested that IRS treatment did not
initiate an early response to SCHU S4 infection (data not shown). At 5 days p.i., the
levels of pro-inflammatory IL-1α, IL-6, TNFα, IL-12p40, IFNγ in the NRS-treated lungs
and livers began to rise above the passively immunized rats and reached significantly
higher levels than IRS-treated rats by 7 days p.i. (Figures 14 and 15). The spleens of the
infected animals showed highest cytokine levels at day 5 p.i. and dropped by 7 days p.i.
At 5 days p.i. IRS-treated rat-spleens had 2-3 times lower levels of cytokines (Figure 16).
In addition, the sera of NRS-treated rats had significantly elevated amounts of cytokines
at both 5 and 7 days after i.t. infection with SCHU S4 (Figure 17). The effect of
upregulated inflammatory mediators on tissue damage was next evaluated by blood
biochemical analysis of sera from both infected and uninfected rats. Suggestive of
decreased liver and kidney injury, IRS-treated rats showed significantly lower levels of
alanine aminotransferase (ALT) and blood urea nitrogen (BUN) in the circulation at 7
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days p.i. (Figure 18). Taken together, these results indicated that IRS treatment is
associated with decreased inflammatory cytokines and tissue injury despite harboring a
high bacterial burden.
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Figure 14. IRS-treated lungs show decreased inflammatory cytokine profiles. Groups (n=3-4) of naïve and
LVS-vaccinated F344 rats were challenged i.t. with ~240 CFU of SCHU S4 after being treated with 250l
of heat-inactivated IRS or NRS 1 d earlier. Lungs were excised at days 2, 5, and 7 days postchallenge and
homogenized in PBS. Supernatants collected from the homogenates were stored at -80 ° C before they
were subjected to luminex analyses. Data shown represents mean +/- SD of duplicate samples of 3-4 rats
from each group at 7 days p.i. from two experiments. Statistical significance of the indicated cytokines was
calculated using one-tailed t test (***, p < 0.0001).
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Figure 15. IRS-treatment is associated with decreased inflammatory cytokine profiles in the liver. Groups
(n=3-4) of naïve and LVS-vaccinated F344 rats were challenged i.t. with ~240 CFU of SCHU S4 after
being treated with 250l of heat-inactivated IRS or NRS 1 d earlier. Livers were excised at days 2, 5, and 7
days postchallenge and homogenized in PBS. Supernatants collected from the homogenates were stored at
-80 ° C before they were subjected to luminex analyses. Data represents mean +/- SD of duplicate samples
of 3-4 rats from each group at 7 days p.i. from two independent experiments. Statistical significance of the
indicated cytokines was calculated using one-tailed t test (**, p < 0.001; ***, p < 0.0001).
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Figure 16. Spleens of IRS-treated show decreased level of hypercytokinemia. Groups (n=3-4) of naïve and
LVS-vaccinated F344 rats were challenged i.t. with ~240 CFU of SCHU S4 after being treated with 250l
of heat-inactivated IRS or NRS 1 d earlier. Spleens were excised at days 2, 5, and 7 days postchallenge and
homogenized in PBS. Supernatants collected from the homogenates were stored at -80 ° C before they
were subjected to luminex analyses. Results shown are mean +/- SD of duplicate samples of 3-4 rats from
each group at day 5 p.i. from two independent experiments. Statistical significance of the indicated
cytokines was calculated using one-tailed t test (**, p < 0.001; ***, p < 0.0001).
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Figure 17. Decreased cytokine levels are seen in sera of IRS-treated animals. Groups (n=3-4) of naïve
F344 rats treated with 250l of PBS or heat-inactivated IRS or NRS. 24h later, the rats were mock-infected
with PBS or challenged i.t. with ~310 CFU of SCHU S4. Sera were collected at 3, 5, and 7 days
postchallenge stored at -80 ° C before they were subjected to luminex analyses. Results shown are mean
+/- SD of duplicate samples of 3-4 rats from each group at the indicated time points from two independent
experiments. Statistical significance was calculated using one-tailed t test (**, p < 0.001; ***, p < 0.0001).
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Figure 18. IRS-treated rats show decreased liver and kidney damage. Groups (n=4) of naïve and LVSvaccinated F344 rats were challenged i.t. with ~260 CFU of SCHU S4 after being treated with 250l of
heat-inactivated IRS or NRS 1 d earlier. Sera were collected at 7 days postchallenge stored at -80 ° C
before analyzing their blood chemistry. Results shown are mean +/- SD from one experiment. Statistical
significance was calculated using one-tailed t test (*, p < 0.05; ***, p < 0.0001).
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Prophylactic IRS treatment is associated with decreased apoptosis in the lungs
Pulmonary infection of mice with type A strains of Ft have been shown to result
in aberrant upregulation of cytokines accompanied with increased apoptosis in the lungs
and systemic organs (53). In our passive immunization studies, histopathological
analysis in SCHU S4 infected rats revealed extensive tissue destruction (Figure 9).
Hence a TUNEL assay was performed on tissue sections processed at different time
points subsequent to i.t. SCHU S4 infection. The number of apoptosing cells in livers
and spleens of both NRS- and IRS-treated rats did not differ significantly at 7 days p.i.
However, the lungs of NRS-treated rats showed distinctly large foci with TUNEL
positive cells at 5 days p.i. (Figure 19A), which diffused and enlarged by 7 days p.i.
(Figure 19D). In contrast, lung tissue sections of IRS-treated rats had far less number of
sparsely distributed TUNEL positive cells (Figure 19C) which remained constant over
the next two days (Figure 19F). LVS-vaccinated rats on the other hand, showed minimal
apoptosis on both 5 and 7 days p.i (Figure 19B and E).
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Figure 19. Lungs of IRS-treated F344 rats show decreased apoptosis during pulmonary SCHU S4
infection. Lungs from naïve F344 rats treated with NRS or IRS and LVS-vaccinated rats were harvested at
5 and 7 days p.i. with SCHU S4 and processed and stained as described in Materials and Methods. In situ
TUNEL was used for indirect detection of apoptotic cells. The lungs of NRS-treated rats had large
TUNEL-positive foci (A and D), while the lungs of IRS-treated rats had fewer and dispersed TUNELpositive cells (C and F). LVS-vaccinated rats had minimal or no apoptotic cells (B and E).
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Immune cell viability in LALNs of IRS-treated F344 rats is not compromised during
pulmonary SCHU S4 infection
Lymphocytes and APCs home to the regional LNs in response to an infection and initiate
adaptive immune responses. To further explore the effect of increased inflammation on
viable cell number and the development of immune responses, LALNs were analyzed
after i.t. SCHU S4 infection. Viable T, B, and DC numbers were quantified at different
time points post-infection to evaluate if the cell death seen in other tissues also extended
to the LALNs. This analysis would also help assess the differences in cell trafficking
kinetics to the LALN between rats that survived and those that succumbed to SCHU S4
infection. As shown in Figure 20, no differences in the viable T and DC numbers were
observed until 7 days p.i., when the NRS-treated rats showed a precipitous drop. Viable
B cells in the IRS-treated rats on the other hand, increased to significantly higher levels at
after 5 days p.i.
The critical role of IFNγ, produced mainly by T cells and to some extent
by NK cells, in protection against Ft infections has been widely documented (119, 164,
187). To determine if the viable cell numbers in the LALN (Figure 20) translated in to
IFNγ production, IFNγ ELISPOT was done using single cell suspensions obtained by
density gradient separation. At both 3 and 7 days p.i. IRS-treated rats had significantly
higher number of IFNγ-producing cells in the LALNs (Figure 21). These results
demonstrate that LALN of IRS-treated rats have significantly high number of IFNγsecreting cells early in the SCHU S4 infection.
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Figure 20. IRS-treated rats do not show decreased viable immune cell numbers in in their LALNs after a
lethal i.t. SCHU S4 infection. Groups of naïve F344 rats were treated with 250µl of heat-inactivated IRS or
NRS and infected i.t. with 210 CFU of SCHU S4 after 24h. Naïve rats treated with PBS and mock-infected
with PBS served as controls. At the indicated time points, LALNs were excised and single cell suspensions
were prepared. Total viable cell number in the LALN of each rat were counted by trypan blue exclusion
before being stained with fluorchrome-conjugated Abs and analyzed by flow cytometry. Data represents
mean +/-SD of 4 animals/grp for each time point. The results represent two experiments for T and B cells
and DC kinetics are from one experiment of similar design. Statistical significance was calculated by onetailed unpaired t test. (*, p < 0.05; **, p < 0.001).
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Figure 21. IRS-treated rats show higher number of IFNγ-secreting cells in the LALN than NRS-treated
rats. Naïve F344 rats were treated with 250µl of heat-inactivated IRS or NRS and infected i.t. with 210
CFU of SCHU S4 the next day. Naïve rats treated with PBS and mock-infected with PBS served as
controls. At the indicated time points, LALNs were excised and single cell suspensions were prepared.
The total number of IFNγ-secreting cells was determined by IFNγ ELISPOT without any antigenic
stimulation as described in Materials and Methods. Data represents mean +/-SD of 4 animals/grp for each
time point. Results from one xperiment are shown. Statistical significance was calculated by one-tailed
unpaired t test. ( p < 0.001; ***, p < 0.0001). SFCs, spot forming cells.
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IRS-treated rats show decreased SCHU S4 burden in the LALNs
The effect of increased cell viability and IFNγ-secreting cells on SCHU S4 burden
in the LALNs was next investigated. Since LVS was shown to utilize the migratory
behavior of immune cells to seed and replicate in the mediastinal LNs during an i.n.
infection (188), the effects of Ab treatment on SCHU S4 growth in LALN was next
investigated. This assay, in addition, would help in understanding the manifestation of
increased cell viability and IFNγ-secreting cells in IRS-treated rats. At 3 days p.i. the
SCHU S4 burden in the LALNs in the rats of both serum-treated groups was similar
(Figure 22), which suggested that IRS treatment did not prevent bacterial dissemination
to LALN unlike liver and spleen (Figure 6). However, unlike the NRS-treated rats which
showed a more or less constant SCHU S4 burden in the LALNs, the bacterial load in the
LALNs of IRS-treated rats dropped to significantly low levels by day 7 p.i. When the
humoral responses in the form of SCHU S4-specific IgM and IgG were tested by ELISA
in the sera at 7 days p.i., the binding titers were not greater than the background in both
NRS-and IRS-treated rats (data not shown). Hence, these data show that IRS treatment
brought about decreased SCHU S4 growth in the LALNs.
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Figure 22. IRS treatment controls SCHU S4 growth in LALNs. Groups of naïve F344 rats were treated with
250µl of heat-inactivated IRS or NRS and infected i.t. with 210 CFU of SCHU S4 after 24h. At the
indicated time points, LALNs were harvested and homogenized using ground slides before the burden was
determined by dilution plating on to cysteine heart agar plates. Results represents mean +/-SD of 4
animals/grp for each time point. One-tailed unpaired t test was used to calculate the statistical significance
(*, p < 0.05).
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IRS treatment generates protective immunity against a high-dose i.t. SCHU S4 challenge
Bacterial burden analyses (Figures 6 and 22) in the IRS-treated rats suggested a
possible development of protective immunity after the low-dose i.t. infection with SCHU
S4. To determine if it did occur, protective immunity development was tested in vivo by
re-infecting the rats with a high dose (2.1 x 104 CFU) of SCHU S4. At this dose, all the
passively immunized rats were shown to succumb to SCHU S4 infection (Table II). Five
weeks after surviving the initial challenge of 240 CFU of SCHU S4, all the IRS-treated
rats were protected upon re-infection with a high-dose of SCHU S4 (Figure 23). The
protection was similar to both the groups of LVS-vaccinated rats. These results suggest
that the IRS treatment enables the development of protective immunity after respiratory
infection with SCHU S4.
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Figure 23. IRS-treated rats develop protective immunity to survive i.t. re-infection with high dose of SCHU
S4. Groups of (n=4-6) naïve and LVS-vaccinated F344 rats along with IRS-treated rats that survived a
lethal i.t. SCHU S4 infection for ~ 5 weeks were infected i.t. with 2.1 x 104 CFU of SCHU and monitored
daily for survival.
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Discussion
Although there is evidence of exotoxin secretion by type A F. tularensis, Abs
may be protective for a multitude of reasons. These may include altering the repertoire of
infected cells during lung infection, limiting the SCHU S4 growth rate, lowering the
magnitude and slowing the course of dissemination, preventing the animals from
developing an irreversible pathological state through adequate adaptive immune response
development. The survival data from the therapeutic Ab treatment study suggest that the
initial 48 h of infection may be decisive in determining the outcome of the infected
animal (Figure 17). This is similar to the observations made by Foshay (177, 178) in
tularemic patients where the poor clinical outcome correlated with a delay in passive Ab
therapy. Similar to our study, delayed Ab administration 2 days after i.n. infection with
LVS killed BALB/c mice (151). The ready availability of Abs and other effector
molecules at the host’s disposal during the early stages of infection when the bacterial
number is low could enable the host to better handle the infection (153). At this stage of
infection, the infection has not progressed to full-blown bacteremia. This may also
explain the loss of protection in our passive immunization model when the challenge
dose was increased (Table II and Figure 12).
While our data suggests the value of LVS-immune Abs in the early phase of
infection (~48 h) with SCHU S4, it did not manifest as decreased bacterial burden in the
sampled tissues in this time frame (Figure 9 and Chapter IV Discussion). This result
appears to conflict with the direct effect of Abs on intracellular SCHU S4 growth in
PBMCs in vitro. While opsonization with LVS-specific Abs significantly enhanced
uptake of SCHU S4 and curbed its fold-increase in 24h, the SCHU S4 numbers remained
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significantly higher than the controls at 24h p.i. (Figure 15). This implies that Abs may
contribute towards increased infection of cells. However, these in vitro findings may
need to be viewed with caution until further investigations are carried in vivo in the
context of whole animal as well as developing in vitro and ex vivo assays with purified
cell populations to dissect Abs’ role on SCHU S4 growth. As demonstrated by Geier et
al. Abs can indeed restrict phagosomal escape and cytosolic proliferation of Francisella
when phagocytosed through FcγRs on macrophages (189). The resulting escalated
superoxide production ultimately led to significantly decreased intracellular growth
(189). Altered intracellular fate of the pathogen through IgG (190) and FcγRs have
similarly been reported for Mycobacterium spps. and Legionella pneumophila (191, 192)
where the IgG/FcγR-mediated endocytic pathways culminated in phago-lysosome fusion
and bacterial degradation.
The reduced tissue damage in the IRS-treated rats may be due to the prevention of
the development of sepsis-like condition reported recently in mice challenged with
SCHU S4 (53). By delaying the hematogenous spread of SCHU S4, IRS might have
averted a dysregulated immune response which results from uncontrolled production of
inflammatory mediators leading to increased vascular permeability, tissue injury, and
organ failure (193, 194). Restricting the tissue destruction may be critical as end-stage
tularemia in humans and non-human primates associated with extensively damaged cells
in the microabcesses and pyogranulomatous necrotic foci of the spleen, liver, and lymph
nodes (182, 195). Similarly, in mice with respiratory tularemia caused by type A strains,
a steep drop in the leukocyte count in the peripheral blood and a significant increase in
the apoptosis of F4/80+ and Ly-6G+ cells in the necrotic areas of liver and spleen has
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been reported (52, 88, 173, 196). Type A strains of Francisella may induce apoptosis of
host cells to evade the host inflammatory responses and disseminate successfully, similar
to several other intracellular pathogens like Salmonella, Yersinia, and Streptococcus
(197-199). Thus, the death of the macrophages in a caspase-3 dependent manner during
pneumonic tularemia may subvert the host innate immune responses and decrease the
survival (51, 52). On the other hand, the host itself may induce apoptosis of the infected
cells in a non-inflammatory manner in the early stages of infection to result in decreased
pathogen viability without injuring the bystander cells. Thus, the direct influence of
LVS-immune Abs on the viability of immune cells and its contribution towards survival
of SCHU S4-infected animals needs to be studied.
The sustained viability of DCs, B, and T cells in the LALNs of IRS-treated rats
may contribute towards rapid and adequate development of adaptive immunity, which is
otherwise dramatically compromised in the NRS-treated rats (Figure 24). Since direct
quantitation of cell death in LNs has not been done, it could be argued that the
disappearance of cells from the LALNs at day 7 p.i. is perhaps due to failure of the
aforementioned cells to home to the LNs or due to their increased egress from LNs to
other anatomic locations where active SCHU S4 multiplication is occurring. However,
this scenario may be unlikely since IRS-treated rats that consistently survive lethal SCHU
S4 challenges had significantly higher viable cell counts than NRS-treated rats, which
usually succumb to SCHU S4 infection. The Ft-specific adaptive T cell responses
measured indirectly through IFNγ ELISPOT in our study may not be an accurate
representation of T cell immunity development in IRS-treated rats, since the T cell counts
are significantly disproportionate between the treatment groups at day 7 p.i. Moreover,
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IFNγ production by non-T and –NK cells (DCs, NK-DCs, macrophages, neutrophils)
further dilutes the clarity of our interpretations (200). Intracellular cytokine staining
would identify specific cell types secreting IFNγ and thereby precisely measure the
adaptive immune response development. Several pathogens exploit the inherent
properties of DCs to phagocytose the invading pathogens. Similar to Mycobacterium,
(201, 202) Ft disseminates and multiplies in the LDLNs mainly by infecting the lung
DCs (188). This ability has been attributed to its virulence during pulmonary infection.
Immune Ab treatment may be preventing the manipulation of lung DC characteristics in
our model since the bacterial burden in the LALNs of IRS-treated rats was significantly
higher than negative controls at 3 days p.i. It must be noted that at the same time point,
SCHU S4 dissemination to liver and spleen was significantly lower than NRS-treated rats
in all the experiments (Figure 9). However, it needs to be determined if SCHU S4
reached the LNs of infected F344 rats alone or in association with DCs as shown by BarHaim et al. with LVS (188). The gradual and significant decline of SCHU S4 in the
LALN of IRS-treated rats by day 7 p.i. may indicate adaptive immune response
development in the LNs.
S. typhimurium (203) and M. tuberculosis (204, 205) have been shown to
undermine the Ag presenting capability of DCs. However, upon targeting Salmonella to
the FcγRs on DCs with specific IgG, the impaired Ag presenting ability was reversed
(203). Although there is no proof yet of type A Ft strains employing the same immune
evasion strategy, Bosio et al. have reported significantly lower MHC II expression on
murine DCs during pulmonary infection with SCHU S4 (55). Further studies on Ab-DC
interactions and kinetics of Ft and immune cell trafficking in the context of our passive
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immunization model are therefore warranted. Overall, our data suggests the possible role
of Abs in rapidly shepherding SCHU S4 to the draining LNs in a form favorable to
eliciting a rapid adaptive immune response, which ultimately confers immunological
advantage to the passively immunized rat.
With regard to the mechanism of Ab-mediated protection against pulmonary
tularemia by type A Ft strains in F344 rats, our data suggests LVS-immune Abs exert
their effect during the first 2 days after infection by acting on the components of the
innate immune system. Since IRS-treatment prevented the development of a hyperinflammatory state associated with immune cell death and tissue damage, the end result
of these as yet unidentified interactions was immunomodulatory in enabling the
development of adaptive immunity and the survival of the infected animals. Indeed,
dysregulated immune response to pulmonary type A Ft infections has been reported to be
associated with poor outcome in mice. Hypercytokinemia observed in various SCHU S4infected tissues (Figures 18 to 21) of NRS-treated rats is an important attribute of sepsis
syndrome. Hyperactive immune response has been shown to ultimately lead to the
development of disseminated intravascular coagulopathy, increased vascular
permeability, and organ injury and failure. IRS treatment may have controlled the
development of unrestrained inflammatory response and thereby prevented the
progression of SCHU S4 infection to a sepsis-like condition. Thus, IRS-treated rats may
have escaped death resulting from type A Ft infections despite high bacterial burden. In
summary, the current study provides a better understanding of SCHU S4 virulence
mechanisms and the role of immune Abs in limiting the pathogenesis and death
associated with lung infection.
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CHAPTER 6: DISCUSSION AND CONCLUSIONS

97

Summary and Future directions
The research study presented herein provides evidence for the protective role of
Abs against pulmonary tularemia caused by type A strains of Ft. The data shows that
while Abs alone significantly prolonged the survival of infected animals in the absence of
T cells, their ability to provide long-term survival critically depended on CD8 T cells. In
addition, immune Ab treatment prevented dissemination of SCHU S4 from the lungs and
was associated with decreased inflammation and tissue damage. By limiting the loss of
immune cell viability, IRS treatment may have allowed for the development of adaptive
immunity, which ultimately helped clear the infection. This concept adds to our
understanding of Abs’ role in pulmonary tularemia caused by SCHU S4 and provides
insight into further studies.
Type A strains of Ft are notorious for the wide array of virulence mechanisms
they employ to successfully evade the host. By being able to be successfully vaccinated
and passively immunized, the F344 rat strain has certain advantages over other rodent
models in studying respiratory tularemia., eExperiments examining the virulence
attributes of SCHU S4 in rats with pneumonic tularemia and how Abs aid in overcoming
these pathogenic mechanisms would further characterize the F344 rat passive
immunization model., In addition, the role of complement in the inflammatory process
has not been tested in this system. With the recent advances in rat gene knockout
technologies (206, 207), delineation of IgG-mediated protective mechanisms is possible.
Signals transduced by cross-linking FcRs through IgG have several downstream
effects on inflammatory processes. The indispensability of IgG for protection against
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SCHU S4 in this study therefore warrants further experimentation on the role of FcRs.
First, signaling cascades and resulting SCHU S4 intracellular fate during FcR-mediated
phagocytosis through IgG opsonization must be compared with those events resulting
from when FcRs alone are engaged. This would help tease out the relative importance
of IgG and FcRs. Second, the synergistic effects of phagocytosis by FcRs and other
phagocytic receptors need to be studied. In the study by Celli & coworkers, although
SCHU S4 uptake by both FcRs andcomplement receptors (CRs) resulted in decreased
phagosomal escape while only FcR-mediated phagocytosis caused respiratory burst,
which enhanced bacterial killing (189). Hence the net result of the combined actions of
these different receptors would be interesting when probed using different opsonins.
Third, since our study clearly points to Ab-mediated effects during the first three days of
SCHU S4 infection, the role of Ab-FcR interactions on chemokine expression in
different cell types must be elucidated. FcR engagement by IgG was shown to induce
MIP-1 and other chemokines in human and mice myeloid leukocytes (208, 209). And
finally, infecting rats with Ab-opsonized SCHU S4 could give us further insight into the
potential outcomes resulting from Ab- FcR interactions.
While macrophages are preferentially infected at a high rate by type A Ft, several
research groups have recently found other cells also to be infected. SCHU S4 mutants,
which cannot replicate in macrophages, were shown to infect and multiply in nonmacrophage cells and cause lethal disease in mice (210). In addition, the invasion of
RBCs reported by the Nau lab has profound implications on the role of Abs in altering
the SCHU S4-infected outcomes (59) since it is therefore possible that Ab opsonization
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of SCHU S4 in vivo could skew towards increased uptake through FcRs and subsequent
killing. This effect of Abs on the repertoire of infected cells could also have
consequences on cell recruitment through Ab-mediated chemokine production. Hence
the percentages of different cell populations and the kinetics of their infection in addition
to their recruitment to the lungs must be tested with fluorochrome-tagged SCHU S4 to
better understand the actions of LVS-specific Abs in the F344 rats.
SCHU S4-infected animals succumb to infection before developing T cell
immunity, the critical importance of which has been exhaustively documented (118-121).
Hence it is possible that the type A strains obstruct multiple steps involved in the
development of T and B cell responses. For example, different pathogens have been
shown to inhibit peptide presentation on MHC molecules (203-205). It needs to be
determined whether SCHU S4 interferes with these pathways and if Abs prevent this
interference and enable primary immune responses in the lymphoid tissues, which is
normally seen during vaccination with live immunogen. Also, it would be interesting to
see if Abs hasten the development of primary immune responses in the regional LNs.
The increased SCHU S4 levels in the LALNs of IRS-treated rats early in the
infection did not correlate with the dissemination to liver and spleen (Figures 9 and 27).
Performing in vivo vital staining experiments would provide information if the pathogen
travelled to the LALNs on its own through capillary leakage or through migrating
phagocytes subsequent to their infection. In addition, the dissemination of SCHU S4 to
LNs and other tissues could be compared at the same time in the same rats to better
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understand the role of Abs in rapid dissemination to the LNs to give a head start in
initiating rapid immune responses.
Our findings point to the critical role of CD8 T cells in protecting the passively
immunized rats (Figure 13). Upon recognition of peptides in context with MHC I
molecules, CD8 T cells primarily mediate their effects against intracellular infections by
causing apoptosis of infected cells induced by perforin and granzyme B or by FasL.
They also secrete IFN and TNF, which have been shown to be critical against Ft
infections. The exact nature of CD8 T cells actions in the context of our passive
immunization model and the influential role(s) of Abs on CD8 T cells must be studied.
A simple and effective way to study the actions of these components is by developing an
in vitro assay similar to the macrophage T cell assay developed by Elkins and coworkers
(122, 123). The effect of Abs and immune T cells alone, and in combination, can then be
evaluated by measuring the SCHU S4 intramacrophage growth and cytokines and other
effector molecules. The assay can be translated in vivo by adoptive transfer of T cells
and Abs and the resulting mechanisms and net effects can be studied and compared.
Thus a clear understanding of how Abs and T cells coordinate during pulmonary Ft
infection could help in designing vaccines with greater efficacy. Besides the timely
development of T cell immunity, immune Abs’ role in controlling the cell death must be
elucidated. The relative levels of different cell death pathways viz. necrosis, apoptosis,
and pyroptosis during pulmonary SCHU S4 infection should be studied with the
availability of appropriate tools for studying rats. Since the bacterial burden the tissues
of both NRS- and IRS-treated rats is more or less similar, limiting the inflammation and
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cell death could be crucial for the positive outcome in IRS-treated rats. Although the
levels of different DAMPs were not measured in the current study, their relevance in
pathogenesis during an infection is gaining ground (211, 212). Elevated levels of highmobility group box-1 (HMGB-1) and other DAMPs have been reported recently in mice
infected i.n. with SCHU S4 (53). While it is possible that a complex interplay of hostand pathogen-derived factors may raise the levels of DAMPs and lead to the development
of sepsis-like condition and multiple organ failure, the direct effect of Abs on the release
of DAMPs must be studied. The LPS levels in the plasma of infected animals could
provide further clues regarding the reduced inflammation in the IRS-treated rats.
Perhaps, Ab binding to Ft surface and subsequent phagocytosis could limit LPS
shedding. The increased LPS levels could trigger an aberrant and chronic activated
inflammatory state and this could be easily tested both in vitro and in vivo. Finally, a
number of in vitro experiments suggested here could be performed with human cell
samples and sera to see if the findings in rats and humans are similar. This would
ultimately aid in designing better vaccines and therapeutics by incorporating Ab
functions in to these designs.

Conclusions
In summary, the results and interpretations described in this manuscript detail the
protective role of immune IgG Abs in protection against respiratory tularemia caused by
the virulent type A strains of Ft. Overall, the data shows that Ab treatment is associated
with decreased inflammation and immune cell death prior to the development of T cell
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immunity. Moreover, the experiments provide the groundwork and clues for
understanding the several other mechanisms through which Abs enhance survival during
respiratory infections with bacterial pathogens. The model ultimately adds significantly
to our understanding of virulence mechanisms of pathogens in general and how Abs
modulate the host-pathogen interactions to have a positive influence on the overall health
of the infected host.
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